Welcome to STN International! Enter x:x

LOGINID:sssptau125rxt

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27	Oct 21	EVENTLINE has been reloaded
NEWS 28	Oct 24	BEILSTEIN adds new search fields
NEWS 29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 31	Nov 18	DKILIT has been renamed APOLLIT
NEWS 32	Nov 25	More calculated properties added to REGISTRY
NEWS 33	Dec 02	TIBKAT will be removed from STN
NEWS 34	Dec 04	CSA files on STN
NEWS 35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36	Dec 17	TOXCENTER enhanced with additional content
NEWS 37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 38	Dec 30	ISMEC no longer available
NEWS 39	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS 40	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS 41	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 42	Feb 13	CANCERLIT is no longer being updated
NEWS 43	Feb 24	METADEX enhancements
NEWS 44	Feb 24	PCTGEN now available on STN
NEWS 45	Feb 24	TEMA now available on STN
NEWS 46	Feb 26	NTIS now allows simultaneous left and right truncation

```
 NEWS 47  Feb 26  PCTFULL now contains images
 NEWS 48  Mar 04  SDI PACKAGE for monthly delivery of multifile SDI results
 NEWS 49  Mar 19  APOLLIT offering free connect time in April 2003
 NEWS 50  Mar 20  EVENTLINE will be removed from STN
 NEWS 51  Mar 24  PATDPAFULL now available on STN
 NEWS 52  Mar 24  Additional information for trade-named substances without
                  structures available in REGISTRY
 NEWS 53  Mar 24  Indexing from 1957 to 1966 added to records in CA/CAPLUS

 NEWS EXPRESS  January 6 CURRENT WINDOWS VERSION IS V6.01a,
               CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
               AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *



FILE 'HOME' ENTERED AT 13:01:20 ON 03 APR 2003

=> file reg
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 13:01:28 ON 03 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    2 APR 2003  HIGHEST RN 501410-52-2
DICTIONARY FILE UPDATES:   2 APR 2003  HIGHEST RN 501410-52-2

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf
```

```
=> s oxandrolone
L1            8 OXANDROLONE

=> d l8
L8 NOT FOUND
The L-number entered has not been defined in this session, or it
has been deleted.  To see the L-numbers currently defined in this
session, enter DISPLAY HISTORY at an arrow prompt (=>).

=> d l1 8

L1   ANSWER 8 OF 8  REGISTRY  COPYRIGHT 2003 ACS
RN   53-39-4  REGISTRY
CN   Cyclopenta[5,6]naphtho[1,2-c]pyran-2(1H)-one, tetradecahydro-7-hydroxy-
     4a,6a,7-trimethyl-, (4aS,4bS,6aS,7S,9aS,9bR,11aS)- (9CI)  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-17-methyl- (7CI, 8CI)
CN   2-Oxaandrostan-3-one, 17-hydroxy-17-methyl-, (5.alpha.,17.beta.)-
OTHER NAMES:
CN   17-Methyl-2-oxa-5.alpha.-androstan-17.beta.-ol-3-one
CN   17.beta.-Hydroxy-17-methyl-2-oxa-5.alpha.-androstan-3-one
CN   17.beta.-Hydroxy-17.alpha.-methyl-2-oxa-5.alpha.-androstan-3-one
CN   8075CB
CN   Anavar
CN   Lonavar
CN   NSC 67068
CN   Oxandren
CN   Oxandrin
CN   Oxandrolone
CN   Protivar
CN   Provitar
CN   SC 11585
CN   Vasorome
FS   STEREOSEARCH
MF   C19 H30 O3
CI   COM
LC   STN Files:   ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
       BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST,
       CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES,
       EMBASE, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, NAPRALERT,
       NIOSHTIC, PHAR, PHARMASEARCH, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN,
       USPAT2, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   EINECS**, WHO
         (**Enter CHEMLIST File for up-to-date regulatory information)
```

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

230 REFERENCES IN FILE CA (1962 TO DATE)
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
230 REFERENCES IN FILE CAPLUS (1962 TO DATE)
22 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.30	6.51

FILE 'CAPLUS' ENTERED AT 13:02:16 ON 03 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 3 Apr 2003 VOL 138 ISS 14
FILE LAST UPDATED: 2 Apr 2003 (20030402/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l1
L2 239 L1

=> d l2 200-239

L2 ANSWER 200 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1970:473524 CAPLUS
DN 73:73524
TI Steroids and nephrectomy cardiopathy
AU Gardell, Claude; Tuchweber, Beatriz; Hatakeyama, Shigeru; Kovacs, Kalman
CS Inst. Med. Chirurg. Exptl., Univ. Montreal, Montreal, Can.
SO Revue Canadienne de Biologie (1970), 29(2), 181-5
CODEN: RCBIAS; ISSN: 0035-0915
DT Journal
LA French

L2 ANSWER 201 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1970:473474 CAPLUS
DN 73:73474
TI Protection by catatoxic steroids against dihydrotachysterol intoxication
AU Selye, Hans; Yeghiayan, E.; Mandeville, Ruth
CS Inst. Med. Chir. Exptl., Univ. Montreal, Montreal, Can.
SO Atherosclerosis (Shannon, Ireland) (1970), 11(2), 321-31
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English

L2 ANSWER 202 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1970:432951 CAPLUS
DN 73:32951
TI Steroid and dietary effects on blood lipids in elderly persons
AU Albanese, Anthony A.; Woodhull, Maurice L.; Orto, Louise A.; Zavattaro, Dorothy N.; Wein, Evelyn H.
CS Nutr. and Metab. Res. Div., Burke Rehabil. Center, White Plains, NY, USA
SO Nutrition Reports International (1970), 1(4), 231-42
CODEN: NURIBL; ISSN: 0029-6635
DT Journal
LA English

L2 ANSWER 203 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1970:402358 CAPLUS
DN 73:2358
TI Protection against methyprylone overdosage by catatoxic steroids
AU Selye, Hans
CS Inst. Med. Chir. Exp., Univ. Montreal, Montreal, Can.
SO Canadian Anaesthetists' Society Journal (1970), 17(2), 107-11
CODEN: CANJAE; ISSN: 0008-2856
DT Journal
LA English

L2 ANSWER 204 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1970:111706 CAPLUS
DN 72:111706
TI 2-Oxa-3-oxo steroids
IN Hara, Shoji
PA Kowa Co., Ltd.
SO Jpn. Tokkyo Koho, 3 pp.
CODEN: JAXXAD
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 45005773	B4	19700226	JP	19640430

L2 ANSWER 205 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1970:109306 CAPLUS
DN 72:109306
TI Prevention of nicotine intoxication by catatoxic steroids
AU Selye, Hans; Yeghiayan, E.; Mecs, Irene
CS Inst. Exp. Med. Surg., Univ. Montreal, Montreal, Can.
SO Archives Internationales de Pharmacodynamie et de Therapie (1970), 183(2), 235-8
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA English

L2 ANSWER 206 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1970:75235 CAPLUS
DN 72:75235
TI Comparative androgenic, myotrophic, and antigonadotrophic properties of some anabolic steroids
AU Boris, Alfred; Stevenson, Richard H.; Trmal, Thelma
CS Res. Div., Hoffmann-La Roche Inc., Nutley, NJ, USA
SO Steroids (1970), 15(1), 61-71
CODEN: STEDAM; ISSN: 0039-128X
DT Journal
LA English

L2 ANSWER 207 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1970:18865 CAPLUS
DN 72:18865
TI Estrogenic and antiestrogenic activities of a number of steroids in behavioral estrus and vaginal smear assays in the ewe
AU Lindsay, D. R.; Scaramuzzi, R. J.
CS Univ. Sydney, Sydney, Australia
SO Journal of Endocrinology (1969), 45(4), 549-55
CODEN: JOENAK; ISSN: 0022-0795
DT Journal
LA English

L2 ANSWER 208 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1969:520149 CAPLUS
DN 71:120149
TI Prevention of digitoxin poisoning by various steroids
AU Selye, Hans; Jelinek, Jan; Krajny, Miloslav
CS Inst. Exp. Med. Surg., Univ. Montreal, Montreal, Can.
SO Journal of Pharmaceutical Sciences (1969), 58(9), 1055-9
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English

L2 ANSWER 209 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1969:93684 CAPLUS
DN 70:93684
TI Nutritional and metabolic effects of anabolic steroids and corticosteroids
AU Albanese, Anthony A.
CS Nutr. and Metab. Res. Div., Burke Rehabil. Center, White Plains, NY, USA
SO Journal of the American Medical Women's Association (1969), 24(1), 42-51
CODEN: JAMWAN; ISSN: 0091-7427
DT Journal
LA English

L2 ANSWER 210 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1969:36402 CAPLUS
DN 70:36402
TI Proper choice of agents to diminish hypercalciuria in urolithiasis
AU Gursel, Erol; Zinsser, Hans H.
CS Coll. of Phys. and Surg., Columbia Univ., New York, NY, USA
SO Medical Times (1968), 96(11), 1133-48
CODEN: METIA9; ISSN: 0092-7309
DT Journal
LA English

L2 ANSWER 211 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1969:614 CAPLUS
DN 70:614
TI Uterotropic activities of some androgenic steroids in the immature mouse
AU Boris, Alfred; Trmal, Thelma
CS Res. Div., Hoffmann-La Roche, Inc., Nutley, NJ, USA
SO Journal Europeen des Steroides (1967), 2(6), 539-45
CODEN: JEPSBL; ISSN: 0531-4186
DT Journal
LA English

L2 ANSWER 212 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1968:493395 CAPLUS
DN 69:93395
TI Anticatabolic applications of newer anabolic steroids
AU Albanese, Anthony A.

CS Burke Rehabilitation Center, White Plains, NY, USA
SO Medical Times (1968), 96(9), 871-81
CODEN: METIA9; ISSN: 0092-7309
DT Journal
LA English

L2 ANSWER 213 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1968:483810 CAPLUS
DN 69:83810
TI Influence of various compounds, particularly steroids, on a transplantable rat mammary fibroadenoma and a transplantable mouse mammary adenocarcinoma
AU Rooks, Wendell H., II; Baba, Shozo; Abe, Osahiko; Harada, Tanekazu; Dorfman, Ralph I.
CS Inst. of Hormone Biol., Syntex Res. Center, Palo Alto, CA, USA
SO Curr. Conc. Breast Cancer, Proc. Symp., New Orleans (1967), Meeting Date 1966, 63-79. Editor(s): Segaloff, Albert. Publisher: Williams and Wilkins Co., Baltimore, Md.
CODEN: 20AFAF
DT Conference
LA English

L2 ANSWER 214 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1968:474303 CAPLUS
DN 69:74303
TI Oxandrolone effect on growth and bone age in idiopathic growth failure
AU Geller, Jack
CS Albert Einstein Coll. of Med., Yeshiva Univ., Bronx, NY, USA
SO Acta Endocrinologica (1968), 59(2), 307-16
CODEN: ACENA7; ISSN: 0001-5598
DT Journal
LA English

L2 ANSWER 215 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1968:408707 CAPLUS
DN 69:8707
TI Effect of oxandrolone on plasma lipids and lipoproteins of patients with disorders of lipid metabolism
AU Sachs, Bernard A.; Wolfman, Lila
CS Med. Div., Montefiore Hosp., Bronx, NY, USA
SO Metabolism, Clinical and Experimental (1968), 17(5), 400-10
CODEN: METAAJ; ISSN: 0026-0495
DT Journal
LA English

L2 ANSWER 216 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1968:570 CAPLUS
DN 68:570
TI Effect of anabolic steroids on plasma glycoproteins
AU Sachs, Bernard A.; Wolfman, Lila
CS Montefiore Hosp. and Med. Center, New York, NY, USA
SO Nature (London, United Kingdom) (1967), 216(5112), 297-8
CODEN: NATUAS; ISSN: 0028-0836
DT Journal
LA English

L2 ANSWER 217 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1967:505680 CAPLUS
DN 67:105680
TI Effects of anabolic steroids in chronic renal failure. I. Short-term effects
AU Sigler, Miles H.; Issekutz, Bela, Jr.
CS Lankenau Hosp., Philadelphia, PA, USA

SO Archives of Internal Medicine (1967), 120(4), 408-16
CODEN: AIMDAP; ISSN: 0003-9926
DT Journal
LA English

L2 ANSWER 218 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1967:112657 CAPLUS
DN 66:112657
TI Relative androgenic activities of some anabolic steroids as measured by chick-comb responses
AU Boris, Alfred; Ng, Chuck
CS Res. Div., Hoffmann-La Roche, Inc., Nutley, NJ, USA
SO Steroids (1967), 9(3), 299-305
CODEN: STEDAM; ISSN: 0039-128X
DT Journal
LA English

L2 ANSWER 219 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1967:11123 CAPLUS
DN 66:11123
TI (Optionally 17-alkylated)-17-oxygenated-3-oxa-5.alpha.-androstan-2-ones and intermediates thereto
IN Pappo, Raphael; Scaros, Mike G.
PA Searle, G. D., and Co.
SO U.S., 3 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 3282962		19661101	US	19641221

L2 ANSWER 220 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1966:450161 CAPLUS
DN 65:50161
OREF 65:9411f-h,9412a
TI Modification of embryonic development of reproductive and lymphoid organs in the chick
AU Erickson, Alan E.; Pincus, Gregory
CS Worcester Found. Exptl. Biol., Shrewsbury, MA
SO J. Embryol. Exptl. Morphol. (1966), 16(1), 211-29
DT Journal
LA English

L2 ANSWER 221 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1966:449474 CAPLUS
DN 65:49474
OREF 65:9295e-f
TI Potent inhibitors of glycine-2-14C uptake in the rat mammary fibroadenoma
AU Rooks, W. H., II; Harada, T.; Baba, S.; Dorfman, R. I.
CS Worcester Found. for Exptl. Biol., Shrewsbury, MA
SO Oncologia (1966), 20(1), 8-10
DT Journal
LA English

L2 ANSWER 222 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1966:440387 CAPLUS
DN 65:40387
OREF 65:7576b-e
TI Effects of androgens, estrogens, and corticoids on strontium kinetics in man

AU Eisenberg, Eugene
CS Univ. of California, San Francisco
SO J. Clin. Endocrinol. Metab. (1966), 26(5), 566-72
DT Journal
LA English

L2 ANSWER 223 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1966:37461 CAPLUS
DN 64:37461
OREF 64:7001g-h
TI Relative effects of 17.alpha.-alkylated anabolic steroids on sulfobromophthalein (BSP) retention in rabbits
AU Lennon, Harry D.
CS G. D. Searle & Co., Chicago
SO J. Pharmacol. Exptl.. Therap. (1966), 151(1), 143-50
DT Journal
LA English

L2 ANSWER 224 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1966:21046 CAPLUS
DN 64:21046
OREF 64:3925d-f
TI Studies of anabolic steroids. III. The effect of oxandrolone on height and skeletal maturation in mongoloid children
AU George Ray, C.; Kirschvink, Joseph F.; Waxman, Sorrell H.; Kelly, Vincent C.
CS Univ. of Washington, Seattle
SO Am. J. Diseases Children (1963), 106, 368-74,375
DT Journal
LA Unavailable

L2 ANSWER 225 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1966:21045 CAPLUS
DN 64:21045
OREF 64:3925d-f
TI Studies of anabolic steroids. III. The effect of oxandrolone on height and skeletal maturation in mongoloid children
AU George Ray, C.; Kirschvink, Joseph F.; Waxman, Sorrell H.; Kelly, Vincent C.
CS Univ. of Washington, Seattle
SO Am. J. Diseases Children (1965), 110(6), 618-23
DT Journal
LA English

L2 ANSWER 226 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:464820 CAPLUS
DN 63:64820
OREF 63:11953d-f
TI Methyltestosterone, related steroids, and liver function
AU DeLorimier, Alfred A.; Gordan, Gilbert S.; Lowe, Rolland C.; Carbone, John V.
CS Univ. of California Med. Center, San Francisco
SO Arch. Intern. Med. (1965), 116(2), 289-94
DT Journal
LA English

L2 ANSWER 227 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:456169 CAPLUS
DN 63:56169
OREF 63:10288d-e
TI Protection by various anabolic steroids against dihydrotachysterol induced calcinosis and catabolism

AU Selye, Hans; Tuchweber, Beatriz; Jacqmin, Marc
CS Univ. Montreal, Can.
SO Acta Endocrinol. (1965), 49(4), 589-602
DT Journal
LA English

L2 ANSWER 228 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:447612 CAPLUS
DN 63:47612
OREF 63:8685c-e
TI Oxandrolone therapy of growth retardation
AU Danowski, T. S.; Lee, F. A.; Cohn, R. E.; D'Ambrosia, R. D.; Limaye, N. R.
CS Univ. of Pittsburgh, Pittsburgh, PA
SO Am. J. Diseases Children (1965), 109(6), 526-32
DT Journal
LA English

L2 ANSWER 229 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:425638 CAPLUS
DN 63:25638
OREF 63:4618b-c
TI Study of calcium metabolism during diffuse disseminated osteopathies with 47Ca. A comparative study of the effect of three anabolic steroids
AU Delaloye, B.; Tabau, R.
CS Univ. Lausanne, Switz.
SO Schweiz. Med. Wochschr. (1964), 94(40), 1410-17
DT Journal
LA French

L2 ANSWER 230 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:75874 CAPLUS
DN 62:75874
OREF 62:13472g-h,13473a
TI Effect of several anabolic steroids on sulfobromophthalein (BSP) retention in rabbits
AU Lennon, Harry D.
SO Steroids (1965), 5(3), 361-73
DT Journal
LA English

L2 ANSWER 231 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:51909 CAPLUS
DN 62:51909
OREF 62:9200f-h,9201a
TI Jervine. XIV. Isojervin-11.beta.-ol and related reduction products of isojervine
AU Wintersteiner, O.; Moore, M.
CS Squibb Inst. for Med. Res., New Brunswick, NJ
SO J. Org. Chem. (1965), 30(2), 528-33
CODEN: JOCEAH; ISSN: 0022-3263
DT Journal
LA English

L2 ANSWER 232 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:45397 CAPLUS
DN 62:45397
OREF 62:8094a-b
TI A quantitative expression for nitrogen retention with anabolic steroids. IV. Oxandrolone
AU Metcalf, William; Blumberg, Harold; Roach, John
CS Albert Einstein Coll. of Med., New York, NY
SO Metab., Clin. Exptl. (1965), 14(1), 59-66

DT Journal
LA English

L2 ANSWER 233 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:23704 CAPLUS
DN 62:23704
OREF 62:4295d-f
TI Anabolic activity of 2-oxa-17.alpha.-methyldihydrotestosterone (Oxandrolone) in castrated rats
AU Lennon, Harry D.; Saunders, Francis J.
CS G. D. Searle & Co., Chicago
SO Steroids (1964), 4(5), 689-97
DT Journal
LA English

L2 ANSWER 234 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1965:9300 CAPLUS
DN 62:9300
OREF 62:1717f-h,1718a-e
TI 17.alpha.-Alkylated 17.beta.-(substituted-oxy)-2-oxa-5.alpha.-androstan-3-ones
IN Pappo, Raphael
PA G.D. Searle & Co.
SO 5 pp.
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3155684		19641103	US	19621029
	GB 988655			GB	

L2 ANSWER 235 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1964:484501 CAPLUS
DN 61:84501
OREF 61:14750c-h
TI 2-Oxa-3-oxosteroids
IN Pappo, Raphael
PA G. D. Searle & Co.
SO 5 pp.
DT Patent
LA Unavailable

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 1171425		19640604	DE	
PRAI	US		19600517		

L2 ANSWER 236 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1964:418478 CAPLUS
DN 61:18478
OREF 61:3170e-h,3171a-d
TI 17-Oxygenated oxa steroids
IN Pappo, Raphael
PA G. D. Searle & Co.
SO 11 pp.
DT Patent
LA Unavailable

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3128283		19640407	US	
PRAI	MX		19610510		

L2 ANSWER 237 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1963:475550 CAPLUS
DN 59:75550
OREF 59:14067e-g
TI 17.beta.-Hydroxy-17.alpha.-methyl,2-oxa-3-oxo-5.alpha.-androstane
IN Pappo, Raphael
PA G. D. Searle & Co.
SO 13 pp.
DT Patent
LA Unavailable

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR M1697		19630318	FR	
	GB 968206			GB	
PRAI	US		19600517		

L2 ANSWER 238 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1963:4327 CAPLUS
DN 58:4327
OREF 58:724g-h,725a
TI Oxandrolone; a potent anabolic steroid of novel chemical configuration
AU Fox, Maurice; Minot, Ann S.; Liddle, Grant W.
CS Vanderbilt Univ., Nashville, TN
SO J. Clin. Endocrinol. Metab. (1962), 22, 921-4
DT Journal
LA Unavailable

L2 ANSWER 239 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1962:449501 CAPLUS
DN 57:49501
OREF 57:9913f-i,9914a-h
TI 2 Oxasteroids. New class of biologically active compounds
AU Pappo, Raphael; Jung, Christopher J.
CS G. D. Searle & Co., Skokie, IL
SO Tetrahedron Letters (1962) 365-71
DT Journal
LA Unavailable

=> d l2 236-239 all

L2 ANSWER 236 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1964:418478 CAPLUS
DN 61:18478
OREF 61:3170e-h,3171a-d
TI 17-Oxygenated oxa steroids
IN Pappo, Raphael
PA G. D. Searle & Co.
SO 11 pp.
DT Patent
LA Unavailable
NCL 260343200
CC 42 (Steroids)

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3128283		19640407	US	
PRAI	MX		19610510		

AB The title compds. were anabolic agents. 17.beta.-Hydroxy-5.alpha.-estran-3-one 2.45, Ac2O 2.2, and C5H5N 20 parts left 16 hrs. at room temp. gave 17.beta.-acetoxy-5.alpha.-estran-3-one (I), m. 104-6.degree.. I 8 in AcOH 63 treated with 2N Br in AcOH 25 parts and stirred 15 min. gave 17.beta.-acetoxy-2-bromo-5.alpha.-estran-3-one (II). II refluxed 15 min.

with collidine gave 17.beta.-acetoxy-5.alpha.-estr-1-en-3-one (III), m. 133.5-5.5.degree., sapond. to 17.beta.-hydroxy-5.alpha.-estr-1-en-3-one. Similarly, 17.beta.-hydroxy-17.alpha.-methyl-5.alpha.-estran-3-one treated with Br and p-MeC6H4SO3H in HCONMe2 gave 2-bromo-17.beta.-hydroxy-17.alpha.-methyl-5.alpha.-estran3-one, which was refluxed 6 hrs. with Li2CO3 and LiCl in HCONMe2 to give 17.beta.-hydroxy-17.alpha.-methyl-5.alpha.-estr-1-en-3-one, m. 141-2.5.degree., [.alpha.]D 87.degree. (CHCl3). Similarly, 17.alpha.-ethyl-17.beta.-hydroxy-5.alpha.-estran-3-one was converted into the 2-bromo compd., and then treated with Li2CO3 and LiCl to give 17.alpha.-ethyl-17.beta.-hydroxy-5.alpha.-estr-1-en-3-one, m. 170-3.degree., [.alpha.]D 42.4.degree.. 5.alpha.-Androst-1-ene-3,17-dione 8 in AcOH 120 and H2O 15 stirred 4 hrs. at room temp. with Pb(OAc)4 50 and OsO4 0.75 part, then 16 hrs. at room temp. gave 1,17-dioxo-1,2-seco-A-norandrostan-2-oic acid (IV). IV reduced at room temp. with NaBH4 in alk. soln. gave 17.beta.-hydroxy-2-oxa-5.alpha.-androstan-3-one (V), m. 198-203.degree.. 17.beta.-Hydroxy-17.alpha.-methyl-5.alpha.-androst-1-en-3-one 63.6 in AcOH 95 and H2O 12 stored 24 hrs. at room temp. with Pb(OAc)4 40 and OsO4 0.6 part gave 17.beta.-hydroxy-17.alpha.-methyl-1-oxo-1,2-seco-Anor-5.alpha.-androstan-2-oic acid (VI), m. 166-73.degree. (decompn.). VI similarly reduced with alk. NaBH4 gave 17.beta.-hydroxy-17.alpha.-methyl-2-oxa-5.alpha.-androstan-3-one, m. 235-8.degree., [.alpha.]D -23.degree. (CHCl3). Similarly, 17.alpha.-ethyl-17.beta.-hydroxy-5.alpha.-androst-1-en-3-one gave 17.alpha.-ethyl-17.beta.-hydroxy-1-oxo-1,2-seco-A-nor-5.alpha.-androstan-2-oic acid and 17.alpha.-ethyl-17.beta.-hydroxy-2-oxa-5.alpha.-androstan-3-one, m. 192-5.degree.. V 3 in Me2CO 40 parts treated with 8N CrO3 in 8N H2SO4 gave 2-oxa-5.alpha.-androstane-3,17-dione, m. 173-4.degree.. 1,4-Androstadiene-3,17-dione 50 in tert-BuOH 546 and H2O 700 left 15 days at room temp. with KClO4 9 and OsO4 4.5 parts gave 4,5-dihydroxy-1-androstene-3,17-dione (VII), m. 203-8.degree. and 1,2-dihydroxy-4-androstene-3,17-dione (VIII), m. 206-10.degree.. A mixt. of VII and VIII in AcOH and H2O treated 1.75 hrs. at 50-60.degree. with Pb(OAc)4 gave 1,17-dioxo-1,2-seco-A-norandrost-3-en-2-oic acid (IX), m. 245-53.degree.. IX 4.75 in CHCl3 12 treated 4 hrs. at room temp. with NaBH4 5 in H2O 60 parts gave 17.beta.-hydroxy-2-oxa-4-androsten-3-one (X), m. 205-7.degree.. 17.beta.-Hydroxy-17.alpha.-methyl-1,4-androstadien-3-one 50 in tert-BuOH 546 and H2O 700 treated 7 days at room temp. with OsO4 4.25 and KClO4 8.5 parts gave 4,5,17.beta.-trihydroxy-17.alpha.-methyl-1-androsten-3-one (XI), m. 199-201.degree., and 1,2,17.beta.-trihydroxy-17.alpha.-methyl-4-androsten-3-one (XII), m. 193-5.5.degree.. A mixt. of XI and XII treated as above with Pb(OAc)4 gave 17.beta.-hydroxy-17.alpha.-methyl-1-oxo-1,2-seco-A-nor-3-androsten-2-oic acid (XIII), m. 250-65.degree.. XIII in CHCl3 reduced with alk. NaBH4 gave 17.beta.-hydroxy-17.alpha.-methyl-2-oxa-4-androsten-3-one, m. 230-40.degree. (decompn.). 17.alpha.-Ethyl-17.beta.-hydroxy-1,4-androstadien-3-one similarly gave 17.alpha.-ethyl-17.beta.-hydroxy-1-oxo-1,2-seco-A-nor-3-androsten-2-oic acid, and then 17.alpha.-ethyl-17.beta.-hydroxy-2-oxa-4-androsten-3-one. X 1 in Me2CO 16 parts treated 5 min. at room temp. with 8N CrO2 and 8N H2SO4 gave 2-oxa-4-androstene-3,17-dione, m. 178-83.degree.. 17.beta.-Hydroxy-17.alpha.-methyl-5.alpha.-androstan-3-one 2.5, isopropenyl acetate 25, and concd. H2SO4 0.2 part distd. slowly in 3 hrs. gave 17.alpha.-methyl-5.alpha.-androst-2-ene-3,17.beta.-diol 3,17.beta.-diacetate (XIV). XIV in EtOAc ozonized at -70.degree., the product reduced with NaBH4, and the org. layer sepd. and acidified gave a crude product (XV). XV heated 7 hrs. with NaOH and H2O gave 2,17.beta.-dihydroxy-17.alpha.-methyl-2,3-seco-5.alpha.-androstan-3-oic acid (XVI), m. 214-15.degree.. XVI in tert-BuPh slowly distd. in 3 hrs. gave 17.beta.-hydroxy- 17.alpha.-methyl-3-oxa-A-homo-5.alpha.-androstan-4-one, m. 241-5.degree.. 2.alpha.,17.beta.-Dihydroxy-17.alpha.-methyl-4-androsten-3-one 1, HIO4 0.8, and C5H5N 10 in H2O 8 parts stored 24 hrs. at room temp. gave 17.beta.-hydroxy-17.alpha.-methyl-2-oxo-2,3-seco-4-androsten-3-oic acid (XVII), m. 219-23.degree. (decompn.). XVII reduced with NaBH4 gave 2,17.beta.-dihydroxy-17.alpha.-

methyl-2,3-seco-4-androsten-3-oic acid (XVIII), m. 182-4.degree.. XVIII refluxed 15 min. in C6H6 gave 17.beta.-hydroxy-17.alpha.-methyl-3-oxa-A-homo-4-androsten-4-one, m. 182-4.degree.. 17.beta.-Hydroxy-2.alpha.,17.alpha.-dimethyl-5.alpha.-androstan-3-one in CH2Cl2 stored 4 days at room temp. with NaOAc and 40% AcO2H in AcOH gave 17.beta.-hydroxy-2.alpha.,17.alpha.-dimethyl-3-oxa-A-homo-5.alpha.-androstan-4-one (XIX), m. 214-30.degree.. XIX 1 in MeOH 16 heated 5 min. with 5% NaOH in H2O 30 parts gave 2.beta.,17.beta.-dihydroxy-2.alpha.,17.alpha.-dimethyl-2,3-seco-5.alpha.-androstan-3-oic acid, m. 190.degree.. VI in tetrahydrofuran treated with MeMgBr gave 17.beta.-hydroxy-1.beta.,17.alpha.-dimethyl-2-oxa-5.alpha.-androstan-3-one, m. 190-201.degree. and 17.beta.-methyl-1.alpha.,17.alpha.-dimethyl-2-oxa-5.alpha.-androstan-3-one, m. 200-5.degree.. Various other related compds. were similarly prepd.

IT Spectra, infrared
Spectra, visible and ultraviolet
(of 2-oxasteroids and precursors)

IT 1H-Benz[e]indene-7-acetic acid, dodecahydro-3-hydroxy-6(2-hydroxypropyl)-3,3a,6-trimethyl-, .epsilon.-lactone
1H-Benz[e]indene-7-acetic acid, dodecahydro-3-hydroxy-6-(2-hydroxyethyl)-3,3a,6-trimethyl-, .epsilon.-lactone
2,3-Seco-5.alpha.-androstan-3-oic acid, 2.beta.,17.beta.-dihydroxy-2,17-dimethyl-
2-Oxasteroids
3-Oxa-A-homo-5.alpha.-androstan-4-one, 17.beta.-hydroxy-17-methyl-
3-Oxa-A-homo-5.alpha.-androstan-4-one, 17.beta.-hydroxy-2.alpha.,17-dimethyl-
3-Oxa-A-homoandrost-4a-en-4-one, 17.beta.-hydroxy-17-methyl-
7H-Benz[e]indene-.DELTA.7,.alpha.-acetic acid, 1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3-hydroxy-6-(2-hydroxyethyl)-3,3a,6-trimethyl-, .epsilon.-lactone

IT **53-39-4**, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-17-methyl- 794-12-7, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy- 798-33-4, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-1.alpha.,17-dimethyl- 901-87-1, 1,2-Seco-A-nor-5.alpha.-androstan-2-oic acid, 17.beta.-hydroxy-17-methyl-1-oxo- 901-88-2, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-1.beta.,17-dimethyl- 903-69-5, 2,3-Secoandrost-4-en-3-oic acid, 2,17.beta.-dihydroxy-17-methyl- 903-69-5, 7H-Benz[e]indene-.DELTA.7,.alpha.-acetic acid, 1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3-hydroxy-6-(2-hydroxyethyl)-3,3a,6-trimethyl- 903-70-8, 2,3-Secoandrost-4-en-3-oic acid, 17.beta.-hydroxy-17-methyl-2-oxo- 903-70-8, 7H-Benz[e]indene-.DELTA.7,.alpha.-acetic acid, 6-(formylmethyl)-1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3-hydroxy-3,3a,6-trimethyl- 1042-56-4, 2-Oxa-5.alpha.,17.alpha.-pregnan-3-one, 17-hydroxy- 1099-81-6, 1H-Benz[e]indene-7-acetic acid, dodecahydro-3-hydroxy-6(2-hydroxypropyl)-3,3a,6-trimethyl- 13974-41-9, 5.alpha.-Estr-1-en-3-one, 17.beta.-hydroxy-17-methyl- 15019-21-3, 5.alpha.-Estr-1-en-3-one, 17.beta.-hydroxy-, acetate 26667-13-0, 2-Oxaandrost-4-ene-3,17-dione 33767-87-2, 5.alpha.-Estran-3-one, 17.beta.-hydroxy-, acetate 54897-10-8, 19-Nor-5.alpha.,17.alpha.-pregn-1-en-3-one, 17-hydroxy- 63973-71-7, 2-Oxaandrost-4-en-3-one, 17.beta.-hydroxy- 73991-16-9, 5.alpha.-Estr-1-en-3-one, 17.beta.-hydroxy- 92473-02-4, 2-Oxaandrost-4-en-3-one, 17.beta.-hydroxy-17-methyl- 94003-59-5, 2-Oxa-5.alpha.-androstane-3,17-dione 94440-68-3, Androst-4-ene-3,17-dione, 1,2-dihydroxy- 94595-21-8, 5.alpha.-Androst-1-ene-3,17-dione, 4,5-dihydroxy- 95168-85-7, Estr-4-ene-16.alpha.,17.beta.-diol 95369-80-5, 5.alpha.-Androstan-3-one, 6.beta.,19-epoxy-17.beta.-hydroxy-17-methyl- 95370-00-6, 5.alpha.-Androst-1-en-3-one, 4,5,17.beta.-trihydroxy-17-methyl- 96364-81-7, Androst-4-en-3-one, 1,2,17.beta.-trihydroxy-17-methyl- 98658-79-8, 7H-Benz[e]indene-.DELTA.7,.alpha.-acetic acid, 6-formyl-1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3a,6-dimethyl-3-oxo-

98843-08-4, 1,2-Seco-A-norandrost-3(5)-en-2-oic acid, 1,17-dioxo-
99729-06-3, 1H-Benz[e]indene-7-acetic acid, 6-formyldodecahydro-3-hydroxy-
3,3a,6-trimethyl- 99785-02-1, 1H-Benz[e]indene-7-acetic acid,
dodecahydro-3-hydroxy-6-(2-hydroxyethyl)-3,3a,6-trimethyl- 100173-14-6,
7H-Benz[e]indene-.DELTA.7,.alpha.-acetic acid, 6-formyl-
1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3-hydroxy-3,3a,6-trimethyl-
105564-75-8, 1,2-Seco-A-norandrost-3(5)-en-2-oic acid,
17.beta.-hydroxy-17-methyl-1-oxo- 106599-27-3,
2,3-Seco-5.alpha.-androstan-3-oic acid, 2,17.beta.-dihydroxy-17-methyl-
(prepn. of)
IT 163-72-4, 6,10-(Epoxymethano)-10H-cyclopenta[a]phenanthrene 219-13-6,
Cyclopenta[5,6]naphtho[1,2-c]pyran
(steroid derivs.)

L2 ANSWER 237 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1963:475550 CAPLUS
DN 59:75550
OREF 59:14067e-g
TI 17.beta.-Hydroxy-17.alpha.-methyl,2-oxa-3-oxo-5.alpha.-androstane
IN Pappo, Raphael
PA G. D. Searle & Co.
SO 13 pp.
DT Patent
LA Unavailable
CC 42 (Steroids)

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR M1697		19630318	FR	
GB 968206			GB	
PRAI US		19600517		

AB The title lactone (I) was prepd. from 17.beta.-hydroxy-17.alpha.-methyl-3-oxo-5.alpha.-androst-1ene (II) via the corresponding hydroxy acid (III). I showed androgenic and myotropic activity with no estrogenic, progestational, or antiinflammatory activity. Thus, 40 parts Pb(AcO)4, 0.6 part OsO4, 6.36 parts II, 95 parts AcOH, and 12 parts H2O was kept at room temp. 24 hrs., treated with 2 parts Pb(AcO)4, evapd. in vacuo, the residue extd. with benzene, the ext. washed with H2O, extd. with aq. KHCO3, the aq. ext. washed with Et2O, acidified with dil. H2SO4, extd. with AcOEtbenzene, the ext. washed with H2O, dried, concd. to dryness, dissolved in 20 parts C5H5N and 10 parts 20% aq. NaHSO3, stirred 20 min., dild. with H2O, washed with AcOEt, acidified with dild. H2SO4, and extd. with benzene to give III. Redn. of III with NaBH4 in aq. NaOH at pH 10 gave I, m. 235-8.degree., [.alpha.]D -23.degree. (c 1, CHCl3).
IT Androgenic hormones or principles
(17.beta.-hydroxy-17-methyl-2-oxa-5.alpha.-androsan-3-one as)
IT Muscles
(17.beta.-hydroxy-17-methyl-2-oxa-5.alpha.-androstan-3-one effect on)
IT Spectra, infrared
(of 17.beta.-hydroxy-17-methyl-2-oxa-5.alpha.-androstan-3-one)
IT **53-39-4**, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-17-methyl-
(prepn. of)
IT 219-13-6, Cyclopenta[5,6]naphtho[1,2-c]pyran
(steroid derivs.)

L2 ANSWER 238 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1963:4327 CAPLUS
DN 58:4327
OREF 58:724g-h,725a
TI Oxandrolone; a potent anabolic steroid of novel chemical configuration
AU Fox, Maurice; Minot, Ann S.; Liddle, Grant W.
CS Vanderbilt Univ., Nashville, TN

SO J. Clin. Endocrinol. Metab. (1962), 22, 921-4
DT Journal
LA Unavailable
CC 58 (Hormones)
AB Oxandrolone (17.alpha.-methyl-2-oxa-5.alpha.-androstan-17.beta.-ol-3-one) was assayed in human subjects by the oral route of administration. The anabolic potency was estd. to be 6.3 times that of methyltestosterone (95% confidence limits 3.8 to 10.6). Perceptible N-sparing activity was noted at a daily dose level of 0.6 mg. Oxandrolone did not suppress corticotropin secretion in man at a dose of 40 mg./day, and had. no effect on circulating eosinophils at dosage levels of 5 and 20 mg. Significant but reversible retention of sulfobromophthalein and slight elevation of serum glutamic-oxalacetic transaminase concns. were noted in most patients treated with 10 mg. daily for 1 month. This compd. had no effect on serum proteins, bilirubin, alk. phosphatase, or cholesterol, or on the cephalin-cholesterol flocculation reaction.
IT **53-39-4**, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-17-methyl-
(effect on N metabolism)
IT 219-13-6, Cyclopenta[5,6]naphtho[1,2-c]pyran
(steroid derivs., effect on N metabolism)

L2 ANSWER 239 OF 239 CAPLUS COPYRIGHT 2003 ACS
AN 1962:449501 CAPLUS
DN 57:49501
OREF 57:9913f-i,9914a-h
TI 2 Oxasteroids. New class of biologically active compounds
AU Pappo, Raphael; Jung, Christopher J.
CS G. D. Searle & Co., Skokie, IL
SO Tetrahedron Letters (1962) 365-71
DT Journal
LA Unavailable
CC 36 (Steroids)
GI For diagram(s), see printed CA Issue.
AB cf. CA 51, 4330c. Treatment of 1 androstene3,17 dione 16 hrs. at 20.degree. with 4 equivs. Pb(OAc)4 in 905% aq. AcOH and the seco aldehyde reduced with aq. NaBH4 followed by acid treatment yielded 50-60% 17.beta.-hydroxy-2-oxa-3-androstanone (I, R = OH, H) (II), m. 198-203.degree., .lambda. 2.75, 5.78 .mu., [.alpha.]24D 1.0.degree., oxidized with CrO3 to I (R = O), m. 174-5.degree., .lambda. 5.77 .mu.. Similar treatment of 17.beta.-hydroxy-17.alpha.-methyl-1-androsten-3 one (III) led to the corresponding 17.beta.-hydroxy-1-oxo-1,2-seco-A-nor-17.alpha.-methylandrostane-2-carboxylic acid, m. 166-73.degree. (decompn.), 2.77, 2.85, 3.70, 5.80 .mu., [.alpha.]25D -22.5.degree., also obtained by Pb(OAc)4 cleavage of 1.alpha.,2.alpha.,17.beta.-trihydroxy-17.alpha.-methyl-3androstanone, m. 180-8.degree. (decompn.), .lambda. 2.80, 2.89, 5.81 .mu., [.alpha.]26D 15.degree., prepd. by hydroxylation of III with KClO3 in the presence of catalytic amts. of OsO4 in aq. Me3COH. The aldehyde acid reduced with NaBH4 gave 1 (R = OH, Me) (IV), m. 235-8.degree., .lambda. 2.87, 5.79 .mu., [.alpha.]25D -23.degree.. Synthesis of the analogous 4,5-unsatd. compds. proved to be considerably more difficult. Treatment of 1,4-androstadiene-3,17-dione in Me3COH with KClO3 in the presence of OsO4 gave mainly V (R = O), m. 205-9.degree., .lambda. 228 m.mu. (.epsilon. 9500, MeOH), .lambda. 2.80, 2.88, 5.76, 5.93 .mu., [.alpha.]28D 151.degree.. The mother liquors fractionally crystd. yielded 10% 1.alpha.,2.alpha.-dihydroxy-4-androstene-3,17-dione (VI, R = |O), |m. 205-9.degree., .lambda. 238 m.mu. (.epsilon. 13,700), .lambda. 2.80, 2.87, 5.75, 5.95, 6.19 .mu., [.alpha.]27D 168.5.degree.. The ketone cleaved with Pb(OAc)4 in aq. AcOH at about 60.degree. gave VII (R = O) (VIII), m. 250-9.degree., .lambda. 226 m.mu. (.epsilon. 14,000), .lambda. 2.80, 3.00, 5.78, 5.88, 6.12 .mu., [.alpha.]27D 279.5.degree. (existing mainly in the lactol form, 1-hydroxy-2oxa-4-androstene-3,17-dione). VIII

in CHCl3 stirred with 1 equiv. NaOH in the presence of excess NaBH4 gave pure 17.beta.-hydroxy-2-oxa-4-androsten-3-one (IX, R = .beta.-OH, H) (X), m. 205-7.degree., .lambda. 223.5 m.mu. (.epsilon. 14,500), .lambda. 2.76, 5.80, 5.88, 6.14 .mu., [.alpha.]28D 173.degree.. Similar treatment of 17.beta.-hydroxy-17.alpha.-methyl-1,4-androstadien-3-one gave predomi-nantly V (R = .beta.-OH, Me) (XI), m. 196-9.degree., .lambda. 229.5 m.mu. (.epsilon. 9350), .lambda. 281, 2.89, 5.93, 6.20 .mu., [.alpha.]26D 57.5.degree.. Fractional crystn. of the mother liquors and removal of residual XI with aq. NaHSO3 in C5H5N gave the required isomeric VI (R = .beta.-OH, Me) (XII), m. 1993.0-5.5.degree., .lambda. 239 m.mu., (.epsilon. 13,300), .lambda. 2.85, 3.00, 5.90, 5.96, 6.1 .mu. (KBr), [.alpha.]27D 63.degree.. XI and XII separately treated with Pb(OAc)4 in AcOH gave 17.beta.hydroxy-3,5-seco-5-oxo-17.alpha.-methyl-A-nor-1-androstene3-carboxylic acid (lactol form, 5,17.beta.-dihydroxy-17.alpha.-methyl-4-oxa-1-androsten-3-one) (XIII), m. 227-30.degree., .lambda. 220 m.mu. (.epsilon. 7500), .lambda. 3.00, 3.15, 5.93, 6.18 .mu., and the lactol VII (R = .beta.-OH, Me) (XIV), m. 250-65.degree., .lambda. 226 m.mu. (.epsilon. 14,200), .lambda. 2.85, 3.05, 5.85, 6.13 .mu. (KBr). Treatment of XIII and XIV in CHCl3 with dil. aq. K2CO3 or Na2CO3 extd. XIII selectively since XIV was only sol. in dil. NaOH. Reduction of XIV in CHCl3 gave 17.beta.-hydroxy-17.alpha.-methyl-2-oxa-4-androsten-3one, (XV), m. 230-40.degree. (decompn.), .lambda. 223.5 m.mu. (.epsilon. 12,500), .lambda. 2.75, 5.78, 5.85, 6.13 .mu., [.alpha.]26D 123.degree.. Application of the same series of reactions to .DELTA.1-progesterone gave a mixt. of 1,2-dihydroxyprogesterone and 4,5-dihydroxy-1-pregnene3,20-dione, converted by treatment with Pb(OAc)4 to a mixt. of VII (R = .beta.-Ac, H) (XVI) and 5-hydroxy-4-oxa-1pregnene-3,20-dione (XVII), sepd. by partition with aq. K2CO3 to give pure XVI, m. 220-3.degree., .lambda. 226.5 m.mu. (.epsilon. 14,300), .lambda. 2.80, 3.00, 5.79, 5.88, 6.12 .mu., [.alpha.]26D 268.degree. (0.5%) and pure XVII, m. 203-6.degree., .lambda. 220 m.mu. (.epsilon. 8300), .lambda. 2.80, 2.97, 5.80, 5.87 .mu., [.alpha.]28D 275.5.degree.. XVI reduced with NaBH4 in a 2 phase system and the epimeric 20-hydroxy compds. oxidized with CrO3 gave IX (R = .beta.-Ac, H) (XVII), m. 168-9.degree., .lambda. 223.9 m.mu. (.epsilon. 14,150), .lambda. 5.80, 5.85, 6.13 .mu., [.alpha.] 26D 237.5.degree.. An analogous series of reactions converted 17.alpha.-acetoxy-.DELTA.1progesterone to 17.alpha.-acetoxy-1-hydroxy-2-oxaprogesterone VII (R = .beta.-Ac, OAc), m. 285.8.degree. (decompn.), .lambda. 226 m.mu. (.epsilon. 14,400), .lambda. 2.75, 2.98, 5.76, 6.10, 7.90 .mu., [.alpha.]24D 137.degree., reduced by NaBH4 in Me2CHOH to give IX (R = .beta.-Ac, OAc) (XVIII), m. 275-9.degree., .lambda. 223.5 m.mu. (.epsilon. 14,900), .lambda. 5.80, 5.83, 6.15, 7.97 .mu., [.alpha.]23D 114.5.degree.. XV is about as anabolic as 17.alpha.-methyltestosterone but only 20% as androgenic by intramuscular injection in the levator ani test. IV was more active than 17.beta.-hydroxy-17.alpha.-methyl-3-androstanone as an oral anabolic agent in the N retention test but is essentially devoid by androgenic properties. XVII and XVIII are about as active as progesterone and 17-acetoxy progesterone resp. in rabbits in the Clauberg assay. The biol. equivalence of the 2-oxa corticoids to the corresponding normal steroids is not compatible with the considerable chem. difference between lactones and ketones and it was assumed that the 3-CO group is not involved chemically in the mechanism of biol. action of these hormones.

IT Spectra, infrared
(of 2-oxasteroids and intermediates)

IT Spectra, visible and ultraviolet
(of 4.alpha.,5-dihydroxy-5.alpha.-androst-1-ene-3,17-dione and congeners)

IT 95126-10-6, 2-Oxaandrost-4-ene-3,17-dione, 1-hydroxy-
(equil. with 1,17-dioxo-1,2-seco-A-norandrost-3(5)-en-2-oic acid)

IT 98658-79-8, 7H-Benz[e]indene-.DELTA.7,.alpha.-acetic acid, 6-formyl-1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3a,6-dimethyl-3-oxo-
98843-08-4, 1,2-Seco-A-norandrost-3(5)-en-2-oic acid, 1,17-dioxo-

(in equil. with 1-hydroxy-2-oxaandrost-4-ene-3,17-dione)
IT 104831-96-1, 4-Oxaandrost-1-en-3-one, 5,17.beta.-dihydroxy-17-methyl-
(in equil. with 17.beta.-hydroxy-17-methyl-5-oxo-3,5-seco-A-norandrost-1-en-3-oic acid)
IT 100150-69-4, 1H-Benz[e]indene-6-acrylic acid, 2,3,3a,4,5,5a,6,7,8,9,9a,9b-dodecahydro-3-hydroxy-3,3a,6-trimethyl-7-oxo- 105564-76-9, 3,5-Seco-A-norandrost-1-en-3-oic acid, 17.beta.-hydroxy-17-methyl-5-oxo-
(in equil. with 5,17.beta.-dihydroxy-17-methyl-4-oxaandrost-1-en-3-one)
IT **53-39-4**, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-17-methyl- 794-12-7, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy- 901-87-1, 1,2-Seco-A-nor-5.alpha.-androstan-2-oic acid, 17.beta.-hydroxy-17-methyl-1-oxo- 1805-13-6, 5.alpha.-Androst-1-ene-3,17-dione, 4.alpha.,5-dihydroxy- 26609-24-5, 2-Oxapregn-4-ene-3,20-dione 38851-97-7, 2-Oxaandrost-4-en-3-one, 1,17.beta.-dihydroxy-17-methyl- 63973-71-7, 2-Oxaandrost-4-en-3-one, 17.beta.-hydroxy- 92473-02-4, 2-Oxaandrost-4-en-3-one, 17.beta.-hydroxy-17-methyl- 94003-59-5, 2-Oxa-5.alpha.-androstane-3,17-dione 94761-20-3, 5.alpha.-Androstan-3-one, 1.alpha.,2.alpha.,17.beta.-trihydroxy-17-methyl- 95172-05-7, 2-Oxapregn-4-ene-3,20-dione, 17-hydroxy-, acetate 95585-10-7, 5.alpha.-Androst-1-en-3-one, 4.alpha.,5,17.beta.-trihydroxy-17-methyl- 95720-13-1, Androst-4-ene-3,17-dione, 1.alpha.,2.alpha.-dihydroxy- 95946-65-9, 2-Oxapregn-4-ene-3,20-dione, 1-hydroxy- 96002-84-5, 2-Oxapregn-4-ene-3,20-dione, 1,17-dihydroxy-, 17-acetate 96478-50-1, Androst-4-en-3-one, 1.alpha.,2.alpha.,17.beta.-trihydroxy-17-methyl- 99729-06-3, 1H-Benz[e]indene-7-acetic acid, 6-formyldodecahydro-3-hydroxy-3,3a,6-trimethyl- 100194-71-6, 4-Oxapregn-1-ene-3,20-dione, 5-hydroxy-
(prepn. of)
IT 219-13-6, Cyclopenta[5,6]naphtho[1,2-c]pyran 219-18-1, Cyclopenta[5,6]naphtho[2,1-b]pyran
(steroid derivs.)

```
=> e dermal
E1            1     DERMAINSPECT/BI
E2            2     DERMAITIS/BI
E3        11724 --> DERMAL/BI
E4            1     DERMALAL/BI
E5            3     DERMALEPIDERMAL/BI
E6            1     DERMALEX/BI
E7            1     DERMALGIA/BI
E8            2     DERMALICHT/BI
E9            1     DERMALIGHT/BI
E10           1     DERMALIN/BI
E11           1     DERMALITIDIS/BI
E12           1     DERMALIVE/BI

=> s e3
L3        11724 DERMAL/BI

=> s l3 and l2
L4            0 L3 AND L2

=> d his

     (FILE 'HOME' ENTERED AT 13:01:20 ON 03 APR 2003)

     FILE 'REGISTRY' ENTERED AT 13:01:28 ON 03 APR 2003
L1            8 S OXANDROLONE

     FILE 'CAPLUS' ENTERED AT 13:02:16 ON 03 APR 2003
L2          239 S L1
                E DERMAL
```

```
L3        11724 S E3
L4            0 S L3 AND L2

=> e theraputic
E1            1     THERAPUEUTIC/BI
E2            2     THERAPUS/BI
E3           24 --> THERAPUTIC/BI
E4            1     THERAPUTICAL/BI
E5            1     THERAPUTICALLY/BI
E6            1     THERAPUTICS/BI
E7            1     THERAPWEUTIC/BI
E8       190584     THERAPY/BI
E9            1     THERAPY1/BI
E10           1     THERAPYEXPRESSION/BI
E11           1     THERAPYIN/BI
E12           2     THERAPYL/BI

=> s e3-e8
             24 THERAPUTIC/BI
              1 THERAPUTICAL/BI
              1 THERAPUTICALLY/BI
              1 THERAPUTICS/BI
              1 THERAPWEUTIC/BI
         190584 THERAPY/BI
L5       190608 (THERAPUTIC/BI OR THERAPUTICAL/BI OR THERAPUTICALLY/BI OR THERAP
                UTICS/BI OR THERAPWEUTIC/BI OR THERAPY/BI)

=> s l2 and l5
L6           41 L2 AND L5

=> d l6 20-41

L6   ANSWER 20 OF 41  CAPLUS  COPYRIGHT 2003 ACS
AN   1997:560862  CAPLUS
DN   127:200215
TI   Oxandrolone, an anabolic steroid, significantly increases the rate of
     weight gain in the recovery phase after major burns
AU   Demling, Robert H.; Desanti, Leslie
CS   Brigham and Women's Hospital Burn Center and Braintree Rehabilitation
     Hospital, Boston, MA, 02115, USA
SO   Journal of Trauma: Injury, Infection, and Critical Care (1997), 43(1),
     47-51
     CODEN: JOTRFA; ISSN: 1079-6061
PB   Williams & Wilkins
DT   Journal
LA   English

L6   ANSWER 21 OF 41  CAPLUS  COPYRIGHT 2003 ACS
AN   1997:392604  CAPLUS
DN   127:117501
TI   Androgen stimulation of lacrimal gland function in mouse models of
     Sjogren's syndrome
AU   Sullivan, David A.; Edwards, Joan A.
CS   Schepens Eye Research Institute and Department of Ophthalmology, Harvard
     Medical School, Boston, MA, 02114, USA
SO   Journal of Steroid Biochemistry and Molecular Biology (1997), 60(3/4),
     237-245
     CODEN: JSBBEZ; ISSN: 0960-0760
PB   Elsevier
DT   Journal
LA   English
```

L6 ANSWER 22 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1997:371563 CAPLUS
DN 127:45182
TI Final height outcome in girls with Turner syndrome treated with a combination of low dose estrogen and oxandrolone
AU Bareille, P.; Massarano, A. a.; Stanhope, R.
CS Med. Unit, Inst. Child Health, London, WC1N 1EH, UK
SO European Journal of Pediatrics (1997), 156(5), 358-362
CODEN: EJPEDT; ISSN: 0340-6199
PB Springer
DT Journal
LA English

L6 ANSWER 23 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1997:165560 CAPLUS
DN 126:233848
TI Growth promotion and Turner-specific bone age after **therapy** with growth hormone and in combination with oxandrolone: when should **therapy** be started in Turner syndrome?
AU Joss, E. E.; Mullis, P. E.; Werder, E. A.; Partsch, C. J.; Sippell, W. G.
CS Department Paediatrics, University Bern, Switz.
SO Hormone Research (1997), 47(3), 102-109
CODEN: HRMRA3; ISSN: 0301-0163
PB Karger
DT Journal
LA English

L6 ANSWER 24 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1997:146236 CAPLUS
DN 126:207687
TI The influence of growth hormone monotherapy and growth hormone in combination with oxandrolone or testosterone on thyroxid hormone parameters and thyroxine binding globulin in patients with Ullrich-Turner syndrome
AU Schmitt, K.; Haeusler, G.; Bluemel, P.; Ploechl, E.; Waldhoer, T.; Frisch, H.
CS Children's Hospital Linz, Linz, A-4020, Austria
SO European Journal of Pediatrics (1997), 156(2), 99-103
CODEN: EJPEDT; ISSN: 0340-6199
PB Springer
DT Journal
LA English

L6 ANSWER 25 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1996:108741 CAPLUS
DN 124:220947
TI Improved final height in girls with Turner's syndrome treated with growth hormone and oxandrolone
AU Nilsson, karl Olof; Albertsson-Wikland, Kerstin; Alm, Jan; Aronson, Stefan; Gustafsson, Jan; Hagenaes, Lars; Haeger, Anders; Ivarsson, Sten A.; Karlberg, Johan; et al.
CS Dep. of Pediatrics and Diagnostic Radiology, Univ. Hospital, Malmo, Swed.
SO Journal of Clinical Endocrinology and Metabolism (1996), 81(2), 635-40
CODEN: JCEMAZ; ISSN: 0021-972X
PB Endocrine Society
DT Journal
LA English

L6 ANSWER 26 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1996:108724 CAPLUS
DN 124:221117
TI Insulin, insulin-like growth factor-binding protein-1, and sex

hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of **therapy** with growth hormone alone and in combination with oxandrolone
AU Haeusler, Gabriele; Schmitt, K.; Bluemel, P.; Ploechl, E.; Waldhoer, Th.; Frisch, H.
CS Pediatric Dep. Inst. Tumor Biol. Cancer Res., Univ. Vienna, Austria
SO Journal of Clinical Endocrinology and Metabolism (1996), 81(2), 536-41
CODEN: JCEMAZ; ISSN: 0021-972X
PB Endocrine Society
DT Journal
LA English

L6 ANSWER 27 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1996:10008 CAPLUS
DN 124:53554
TI Immunocytochemical location and hormonal control of androgen receptors in lacrimal tissues of the female MRL/Mp-lpr/lpr mouse model of Sjogren's syndrome
AU Ono, Masafumi; Rocha, Flavio Jaime; Sullivan, David A.
CS Schepens Eye Res. Inst., Boston, MA, USA
SO Experimental Eye Research (1995), 61(6), 659-66
CODEN: EXERA6; ISSN: 0014-4835
PB Academic
DT Journal
LA English

L6 ANSWER 28 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1994:622993 CAPLUS
DN 121:222993
TI Methods and formulations for use in treating oophorectomized women
IN Pike, Malcolm C.; Spicer, Darcy V.
PA University of Southern California, USA
SO U.S., 7 pp. Cont.-in-part of U.S. Ser. No. 952,513.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5340586	A	19940823	US 1993-62886	19930517
	US 5211952	A	19930518	US 1991-684612	19910412
	US 5340584	A	19940823	US 1993-952513	19930201
	WO 9426208	A1	19941124	WO 1994-US5262	19940512
	W: CA, FI, NO				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 748191	A1	19961218	EP 1994-917357	19940512
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	NO 9504612	A	19960112	NO 1995-4612	19951115
PRAI	US 1991-684612		19910412		
	US 1993-952513		19930201		
	WO 1992-US2973		19920410		
	US 1993-62886		19930517		
	WO 1994-US5262		19940512		

L6 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1994:24366 CAPLUS
DN 120:24366
TI Ocular androgen **therapy** in Sjogren's syndrome
IN Sullivan, David A.
PA Schepen's Eye Research Institute, Inc., USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9320823	A1	19931028	WO 1993-US3801	19930421
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9341121	A1	19931118	AU 1993-41121	19930421
	AU 674681	B2	19970109		
	EP 643581	A1	19950322	EP 1993-910732	19930421
	EP 643581	B1	19991020		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07508716	T2	19950928	JP 1993-518700	19930421
	CA 2133966	C	19970909	CA 1993-2133966	19930421
	AT 185697	E	19991115	AT 1993-910732	19930421
	ES 2139005	T3	20000201	ES 1993-910732	19930421
PRAI	US 1992-871657	A	19920421		
	WO 1993-US3801	A	19930421		

L6 ANSWER 30 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1990:565620 CAPLUS
DN 113:165620
TI Effect of oxandrolone and growth hormone on growth rate in Turner syndrome
AU Park, Kwang Sun; Lee, Byung Churl
CS Med. Coll., Cathol. Univ., Seoul, S. Korea
SO K'at'ollik Taehak Uihakpu Nonmunjip (1990), 43(1), 139-46
CODEN: KTUNAA; ISSN: 0368-7015
DT Journal
LA Korean

L6 ANSWER 31 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1986:603364 CAPLUS
DN 105:203364
TI The effect of oxandrolone on the growth hormone response to growth hormone-releasing hormone in children with constitutional growth delay
AU Loche, S.; Corda, R.; Lampis, A.; Puggioni, R.; Cella, S. G.; Muller, E. E.; Pintor, Carlo
CS 1st Dep. Pediatr., Univ. Cagliari, Cagliari, Italy
SO Clinical Endocrinology (Oxford, United Kingdom) (1986), 25(2), 195-200
CODEN: CLECAP; ISSN: 0300-0664
DT Journal
LA English

L6 ANSWER 32 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1986:45939 CAPLUS
DN 104:45939
TI The effect of androgens on the pulsatile release and the twenty-four-hour mean concentration of growth hormone in peripubertal males
AU Link, Kathleen; Blizzard, Robert M.; Evans, William S.; Kaiser, Donald L.; Parker, Mark W.; Rogol, Alan D.
CS Med. Cent., Univ. Virginia, Charlottesville, VA, 22908, USA
SO Journal of Clinical Endocrinology and Metabolism (1986), 62(1), 159-64
CODEN: JCEMAZ; ISSN: 0021-972X
DT Journal
LA English

L6 ANSWER 33 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1980:209155 CAPLUS
DN 92:209155
TI High density lipoproteins during hypolipidemic **therapy**. A comparative study of four drugs

AU Cheung, Marian C.; Albers, John J.; Wahl, Patricia W.; Hazzard, William R.
CS Northwest Lipid Res. Clin., Univ. Washington, Seattle, WA, 98104, USA
SO Atherosclerosis (Shannon, Ireland) (1980), 35(3), 215-28
CODEN: ATHSBL; ISSN: 0021-9150
DT Journal
LA English

L6 ANSWER 34 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1975:491060 CAPLUS
DN 83:91060
TI Efficacy and interactions of oxandrolone, halofenate, and clofibrate in a factorial study on experimental acute nephrotic hyperlipidemia
AU Schapel, G. J.; Edwards, K. D. G.
CS Kanematsu Mem. Inst., Sydney Hosp., Sydney, Australia
SO Journal of Pharmacology and Experimental Therapeutics (1975), 194(1), 274-84
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA English

L6 ANSWER 35 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1974:461630 CAPLUS
DN 81:61630
TI Bone turnover-sex hormone-parathyroid hormone interrelations in postmenopausal osteoporosis
AU Riggs, B.; Jowsey, J.; Kelly, P. J.; Arnaud, C. D.
CS Mayo Clin. Mayo Med. Sch., Rochester, MN, USA
SO Bollettino - Societa Italiana di Biologia Sperimentale (1973), 49(12), 732-7
CODEN: BSIBAC; ISSN: 0037-8771
DT Journal
LA English

L6 ANSWER 36 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1969:93684 CAPLUS
DN 70:93684
TI Nutritional and metabolic effects of anabolic steroids and corticosteroids
AU Albanese, Anthony A.
CS Nutr. and Metab. Res. Div., Burke Rehabil. Center, White Plains, NY, USA
SO Journal of the American Medical Women's Association (1969), 24(1), 42-51
CODEN: JAMWAN; ISSN: 0091-7427
DT Journal
LA English

L6 ANSWER 37 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1969:36402 CAPLUS
DN 70:36402
TI Proper choice of agents to diminish hypercalciuria in urolithiasis
AU Gursel, Erol; Zinsser, Hans H.
CS Coll. of Phys. and Surg., Columbia Univ., New York, NY, USA
SO Medical Times (1968), 96(11), 1133-48
CODEN: METIA9; ISSN: 0092-7309
DT Journal
LA English

L6 ANSWER 38 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1968:493395 CAPLUS
DN 69:93395
TI Anticatabolic applications of newer anabolic steroids
AU Albanese, Anthony A.
CS Burke Rehabilitation Center, White Plains, NY, USA
SO Medical Times (1968), 96(9), 871-81

CODEN: METIA9; ISSN: 0092-7309
DT Journal
LA English

L6 ANSWER 39 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1968:474303 CAPLUS
DN 69:74303
TI Oxandrolone effect on growth and bone age in idiopathic growth failure
AU Geller, Jack
CS Albert Einstein Coll. of Med., Yeshiva Univ., Bronx, NY, USA
SO Acta Endocrinologica (1968), 59(2), 307-16
CODEN: ACENA7; ISSN: 0001-5598
DT Journal
LA English

L6 ANSWER 40 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1968:570 CAPLUS
DN 68:570
TI Effect of anabolic steroids on plasma glycoproteins
AU Sachs, Bernard A.; Wolfman, Lila
CS Montefiore Hosp. and Med. Center, New York, NY, USA
SO Nature (London, United Kingdom) (1967), 216(5112), 297-8
CODEN: NATUAS; ISSN: 0028-0836
DT Journal
LA English

L6 ANSWER 41 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1965:447612 CAPLUS
DN 63:47612
OREF 63:8685c-e
TI Oxandrolone **therapy** of growth retardation
AU Danowski, T. S.; Lee, F. A.; Cohn, R. E.; D'Ambrosia, R. D.; Limaye, N. R.
CS Univ. of Pittsburgh, Pittsburgh, PA
SO Am. J. Diseases Children (1965), 109(6), 526-32
DT Journal
LA English

=> d l6 36 32 29 28 all

L6 ANSWER 36 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1969:93684 CAPLUS
DN 70:93684
TI Nutritional and metabolic effects of anabolic steroids and corticosteroids
AU Albanese, Anthony A.
CS Nutr. and Metab. Res. Div., Burke Rehabil. Center, White Plains, NY, USA
SO Journal of the American Medical Women's Association (1969), 24(1), 42-51
CODEN: JAMWAN; ISSN: 0091-7427
DT Journal
LA English
CC 4 (Hormones)
AB The steroid protein activity index (SPAI), a measurement of anabolic activity, was reported for orally administered anabolic steroids (testosterone propionate, 19-nortestosterone, norethandrolone, oxandrolone, 4-hydroxy-17.alpha.-methyltestosterone, methandrostenolone, stanozolol, norbolethione, 17.beta. - trimethylsiloxyandrost-4-en-3-one, BAS-71, and 17.beta.-hydroxy-2-oxa-19-norandrosta-4,9(10)-dien-3-one), corticosteroids (prednisone, prednisolone, triamcinolone, dexamethasone, paramethasone, betamethasone, and fluocortolone), as well as for parenteral anabolic steroids (dromostanolone propionate, stanozolol, methenolone enanthate, bolmantalate, oxandrolone, bolandiol dipropionate (SC-7525), SKF-6611, and SKF-8048). Trials with the oral administration

of corticosteroids, followed by a period of combined corticosteroid and anabolic steroid **therapy**, permitted the detn. of the anticor-ticocatabolic activity index (ACAI). From this, the pos. action of the anabolic steroids on N retention could be quantitated and dosage relation established.

ST anabolic steroids activity; corticoids anabolic steroids; steroids anabolic corticoids; steroid protein activity index

IT Proteins
RL: BIOL (Biological study)
(metabolic retention of, detn. of steroid action on)

IT BAS 71
RL: BIOL (Biological study)
(nitrogen retention response to, calcn. of)

IT Cyclopenta[5,6]naphtho[1,2-c]pyran, oxasteroid derivs.
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

IT 50-02-2, biological studies 50-24-8, biological studies 52-78-8 53-03-2 53-33-8 **53-39-4** 57-85-2 72-63-9 124-94-7 145-12-0 152-97-6 302-96-5 303-42-4 378-44-9 434-22-0 521-12-0 797-58-0 1164-99-4 1491-81-2 1986-53-4 5055-42-5 20111-37-9 22467-98-7
RL: BIOL (Biological study)
(nitrogen retention response to, calcn. of)

L6 ANSWER 32 OF 41 CAPLUS COPYRIGHT 2003 ACS

AN 1986:45939 CAPLUS

DN 104:45939

TI The effect of androgens on the pulsatile release and the twenty-four-hour mean concentration of growth hormone in peripubertal males

AU Link, Kathleen; Blizzard, Robert M.; Evans, William S.; Kaiser, Donald L.; Parker, Mark W.; Rogol, Alan D.

CS Med. Cent., Univ. Virginia, Charlottesville, VA, 22908, USA

SO Journal of Clinical Endocrinology and Metabolism (1986), 62(1), 159-64
CODEN: JCEMAZ; ISSN: 0021-972X

DT Journal

LA English

CC 2-4 (Mammalian Hormones)

AB The effects of oxandrolone (Ox) [**53-39-4**] and testosterone (T) [58-22-0] on the mean concn. of growth hormone (GH) [9002-72-6], the pattern of GH secretion, and somatomedin C (SmC) [67763-96-6] concns. in boys with short stature and (or) delayed sexual development were studied to det. whether their growth-promoting effects might be mediated through endogenous GH release. Ten boys received Ox (0.1 mg/kg/day, orally) for 65 days, and 5 boys received T propionate (7.5 mg, i.m., for 7 days), followed by T enanthate (100 mg, i.m., monthly for 3 mo). Serum GH was measured in samples obtained at 20-min intervals for 24 h before and 65 days after the initiation of **therapy**. SmC levels were measured twice during the same 24-h period before and 65 days after initiation of **therapy**. In the boys treated with T, there were increases in the mean concn. of GH (4.3-fold), in the no. of GH pulses .gtoreq.10 ng/mL, (1.6 vs. 4.8/24 h), and in the SmC levels (0.82 vs. 2.3 .mu./mL). There were, however, no significant changes in the boys treated with Ox. Both Ox and T improved the growth rates; however, T increased the growth rate by 0.95 cm/mo, and Ox increased the growth rate by 0.24 cm/mo. Thus, T, but not Ox, at the doses tested increases GH secretion in boys with short stature and (or) delayed sexual development. This increase in GH secretion may contribute to the increased growth rate in males at puberty.

ST androgen somatotropin secretion puberty; testosterone somatotropin secretion puberty; oxandrolone somatotropin secretion puberty; growth hormone secretion androgen

IT Blood serum
(growth hormone and somatomedin C of, of boy in puberty, androgens

effect on)
IT Androgens
RL: BIOL (Biological study)
(growth hormone secretion response to, in puberty in boy)
IT Puberty
(male, growth hormone secretion in, in boy, androgens effect on)
IT **53-39-4** 58-22-0
RL: BIOL (Biological study)
(growth hormone secretion response to, in puberty in boy)
IT 67763-96-6
RL: BIOL (Biological study)
(of blood serum, of boy in puberty, androgens effect on)
IT 9002-72-6
RL: BIOL (Biological study)
(secretion of, by boy in puberty, androgens effect on)

L6 ANSWER 29 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1994:24366 CAPLUS
DN 120:24366
TI Ocular androgen **therapy** in Sjogren's syndrome
IN Sullivan, David A.
PA Schepen's Eye Research Institute, Inc., USA
SO PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-56
CC 2-4 (Mammalian Hormones)
Section cross-reference(s): 1, 63
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9320823	A1	19931028	WO 1993-US3801	19930421
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9341121	A1	19931118	AU 1993-41121	19930421
	AU 674681	B2	19970109		
	EP 643581	A1	19950322	EP 1993-910732	19930421
	EP 643581	B1	19991020		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 07508716	T2	19950928	JP 1993-518700	19930421
	CA 2133966	C	19970909	CA 1993-2133966	19930421
	AT 185697	E	19991115	AT 1993-910732	19930421
	ES 2139005	T3	20000201	ES 1993-910732	19930421
PRAI	US 1992-871657	A	19920421		
	WO 1993-US3801	A	19930421		

AB The topical application to the ocular surface or adjacent regions of the eye of a prepn. contg. a therapeutic amt. of an androgen or androgen analog is disclosed as a method of relieving the chronic and acute manifestation of dry eye symptoms in Sjogren's syndrome. Effects of e.g. testosterone in a mouse model for Sjogren's syndrome are reported.
ST androgen Sjogren syndrome keratoconjunctivitis sicca; testosterone Sjogren syndrome keratoconjunctivitis sicca; ophthalmic androgen Sjogren syndrome keratoconjunctivitis sicca; dry eye Sjogren syndrome androgen
IT Lymphocyte
(androgen **therapy** effect on Ia-pos., in lacrimal tissue of Sjogren syndrome mouse model)
IT Sjogren's syndrome
(androgens for treatment of dry-eye symptoms in)
IT Tear
(deficiency of, in keratoconjunctivitis sicca, treatment of, androgens for)

IT Androgens
RL: BIOL (Biological study)
(dry-eye symptoms in Sjogren's syndrome treatment with)
IT Lymphocyte
(B-cell, androgen **therapy** effect on, in lacrimal tissue of Sjogren syndrome mouse model)
IT Histocompatibility antigens
RL: BIOL (Biological study)
(Ia (H-2 I-region-assocd.), androgen **therapy** effect on, in lacrimal tissue of Sjogren syndrome mouse model)
IT Lymphocyte
(T-cell, androgen **therapy** effect on, in lacrimal tissue of Sjogren syndrome mouse model)
IT Lymphocyte
(T-cell, cytotoxic, androgen **therapy** effect on, in lacrimal tissue of Sjogren syndrome mouse model)
IT Lymphocyte
(T-cell, helper cell, androgen **therapy** effect on, in lacrimal tissue of Sjogren syndrome mouse model)
IT Lymphocyte
(T-cell, suppressor cell, androgen **therapy** effect on, in lacrimal tissue of Sjogren syndrome mouse model)
IT Lacrimal gland
(disease, testosterone effect on, in mouse Sjogren syndrome model)
IT Eye, disease
(keratoconjunctivitis sicca, tear deficiency in, treatment of, androgens for)
IT Pharmaceutical dosage forms
(ophthalmic, of androgens, for dry-eye symptom treatment in Sjogren's syndrome)
IT **53-39-4** 58-22-0D, derivs. 434-22-0D, derivs. 521-18-6D, 4,5.alpha.-Dihydrotestosterone, derivs. 1225-43-0D, 17.beta.-Hydroxy-5.alpha.-androstane, ring A-unsatd. derivs.
RL: BIOL (Biological study)
(dry-eye symptoms in Sjogren's syndrome treatment with)
IT 58-22-0, Testosterone 434-22-0, 19-Nortestosterone
RL: BIOL (Biological study)
(lacrimal gland immunopathol. of mouse Sjogren syndrome mouse model in presence of)

L6 ANSWER 28 OF 41 CAPLUS COPYRIGHT 2003 ACS
AN 1994:622993 CAPLUS
DN 121:222993
TI Methods and formulations for use in treating oophorectomized women
IN Pike, Malcolm C.; Spicer, Darcy V.
PA University of Southern California, USA
SO U.S., 7 pp. Cont.-in-part of U.S. Ser. No. 952,513.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K009-50
ICS A61K009-14
NCL 424426000
CC 2-4 (Mammalian Hormones)
Section cross-reference(s): 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5340586	A	19940823	US 1993-62886	19930517
	US 5211952	A	19930518	US 1991-684612	19910412
	US 5340584	A	19940823	US 1993-952513	19930201
	WO 9426208	A1	19941124	WO 1994-US5262	19940512

W: CA, FI, NO
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
EP 748191 A1 19961218 EP 1994-917357 19940512
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
NO 9504612 A 19960112 NO 1995-4612 19951115
PRAI US 1991-684612 19910412
US 1993-952513 19930201
WO 1992-US2973 19920410
US 1993-62886 19930517
WO 1994-US5262 19940512

AB Compns. and methods which are effective to prevent symptoms of loss of ovarian function (e.g., in oophorectomized women) over a period of time are described, consisting essentially of an effective amt. of an estrogenic compn. and an effective amt. of an androgenic compn. The levels of estrogens and androgens employed are sufficient to reduce bone mineral d. loss and minimize other side effects obsd. after oophorectomy, and at such low doses as to minimize any adverse impact on the patient's long-term prognosis or (in the case of testosterone) result in addnl. side effects.

ST oophorectomy estrogen androgen combined **therapy**

IT Ovariectomy
(ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Androgens
Estrogens
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Ovary, disease
(failure, oophorectomy symptoms treatment with estrogen and androgen combinations)

IT Pharmaceutical dosage forms
(injections, i.m., ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Pharmaceutical dosage forms
(injections, s.c., ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Pharmaceutical dosage forms
(transdermal, ovarian failure symptoms treatment with estrogen and androgen combinations)

IT Pharmaceutical dosage forms
(vaginal, ovarian failure symptoms treatment with estrogen and androgen combinations)

IT 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-50-0, Estradiol benzoate 53-16-7, Estrone, biological studies **53-39-4**, Oxandrolone 56-53-1, Diethylstilbestrol 57-63-6, Ethinyl estradiol 57-85-2, Testosterone propionate 58-18-4, Methyltestosterone 58-19-5, Dromostanolone 58-20-8, Testosterone cypionate 58-22-0, Testosterone 63-05-8, Androstenedione 72-33-3, Mestranol 152-43-2, Quinestrol 313-06-4, Estradiol cypionate 315-37-7, Testosterone enanthate 360-70-3, Nandrolone decanoate 434-07-1, Oxymethalone 434-22-0, Nandrolone 514-68-1 517-09-9, Equilenin 521-10-8, Methandriol 521-18-6, Dihydrotestosterone 965-90-2, Ethylestrenol 968-93-4, Testolactone 979-32-8, Estradiol valerate 1240-04-6 7280-37-7, Piperazine estrone sulfate 10418-03-8, Stanozolol 15183-37-6, Estetrol 17230-88-5, Danazol 27651-95-2, Equilenin sulfate 28014-46-2, Polyestradiol phosphate 147827-23-4, Pinestrol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ovarian failure symptoms treatment with estrogen and androgen combinations)

```
=> d his

     (FILE 'HOME' ENTERED AT 13:01:20 ON 03 APR 2003)

     FILE 'REGISTRY' ENTERED AT 13:01:28 ON 03 APR 2003
L1             8 S OXANDROLONE

     FILE 'CAPLUS' ENTERED AT 13:02:16 ON 03 APR 2003
L2           239 S L1
                 E DERMAL
L3         11724 S E3
L4             0 S L3 AND L2
                 E THERAPUTIC
L5        190608 S E3-E8
L6            41 S L2 AND L5

=> e injection
E1             6     INJECTIOIN/BI
E2             1     INJECTIOION/BI
E3        410596 --> INJECTION/BI
E4             1     INJECTION2/BI
E5            10     INJECTIONABLE/BI
E6            13     INJECTIONAL/BI
E7             2     INJECTIONALLY/BI
E8             1     INJECTIONAN/BI
E9             1     INJECTIONAND/BI
E10            2     INJECTIONCOOKING/BI
E11            1     INJECTIONDIODES/BI
E12            9     INJECTIONE/BI

=> s e3
L7        410596 INJECTION/BI

=> s l7 and l2
L8             9 L7 AND L2

=> d l8 1-9

L8   ANSWER 1 OF 9  CAPLUS  COPYRIGHT 2003 ACS
AN   1992:188207  CAPLUS
DN   116:188207
TI   The effects of an anabolic steroid (oxandrolone) on reproductive
     development in the male rat
AU   Grokett, Bernard H.; Ahmad, Nazir; Warren, Dwight W.
CS   Dep. Exercise Sci., Univ. South. California, Los Angeles, CA, 90033, USA
SO   Acta Endocrinologica (1992), 126(2), 173-8
     CODEN: ACENA7; ISSN: 0001-5598
DT   Journal
LA   English

L8   ANSWER 2 OF 9  CAPLUS  COPYRIGHT 2003 ACS
AN   1991:254029  CAPLUS
DN   114:254029
TI   Compositions useful as contraceptives in males
IN   Cohen, Michael
PA   Neth.
SO   PCT Int. Appl., 31 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.       KIND  DATE          APPLICATION NO.  DATE
```

PI	WO 9100095	A1	19910110	WO 1990-NL90	19900626
	W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	IN 171596	A	19921121	IN 1990-MA495	19900620
	CA 2059138	AA	19901228	CA 1990-2059138	19900626
	AU 9059683	A1	19910117	AU 1990-59683	19900626
	AU 639467	B2	19930729		
	DD 297327	A5	19920109	DD 1990-342103	19900626
	EP 479867	A1	19920415	EP 1990-910521	19900626
	EP 479867	B1	19960515		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	DD 299619	A5	19920430	DD 1990-344095	19900626
	IL 94869	A1	19941007	IL 1990-94869	19900626
	JP 07507037	T2	19950803	JP 1990-510056	19900626
	AT 137970	E	19960615	AT 1990-910521	19900626
	CN 1048327	A	19910109	CN 1990-103286	19900627
	ZA 9005020	A	19910424	ZA 1990-5020	19900627
PRAI	US 1989-371794		19890627		
	WO 1990-NL90		19900626		
OS	MARPAT 114:254029				

L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1990:93339 CAPLUS
DN 112:93339
TI Micellar liquid chromatography for rapid screening of illegal drugs in sport
AU Berthod, A.; Asensio, J. M.; Laserna, J. J.
CS Lab. Sci. Anal., Univ. Lyon I, Villeurbanne, 69622, Fr.
SO Journal of Liquid Chromatography (1989), 12(13), 2621-34
CODEN: JLCHD8; ISSN: 0148-3919
DT Journal
LA English

L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1975:149768 CAPLUS
DN 82:149768
TI Effects of glucocorticoid hormone on lipid and carbohydrate metabolism. II. Effect of glucocorticoid hormone on lipid metabolism
AU Kikuchi, Takahisa
CS Dep. Intern. Med., Okayama Univ., Okayama, Japan
SO Okayama Igakkai Zasshi (1974), 86(11-12), 553-65
CODEN: OIZAAV; ISSN: 0030-1558
DT Journal
LA Japanese

L8 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1973:80474 CAPLUS
DN 78:80474
TI Influence of catatoxic steroids upon acute and chronic aniline toxicity
AU Lefebvre, Francine; Szabo, Sandor
CS Inst. Med. Chir. Exp., Univ. Montreal, Montreal, QC, Can.
SO Journal de Physiologie (Paris, 1946-1992) (1972), 63(5), 611-16
CODEN: JOPHAN; ISSN: 0021-7948
DT Journal
LA French

L8 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1970:18865 CAPLUS
DN 72:18865

TI Estrogenic and antiestrogenic activities of a number of steroids in behavioral estrus and vaginal smear assays in the ewe
AU Lindsay, D. R.; Scaramuzzi, R. J.
CS Univ. Sydney, Sydney, Australia
SO Journal of Endocrinology (1969), 45(4), 549-55
CODEN: JOENAK; ISSN: 0022-0795
DT Journal
LA English

L8 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1966:440387 CAPLUS
DN 65:40387
OREF 65:7576b-e
TI Effects of androgens, estrogens, and corticoids on strontium kinetics in man
AU Eisenberg, Eugene
CS Univ. of California, San Francisco
SO J. Clin. Endocrinol. Metab. (1966), 26(5), 566-72
DT Journal
LA English

L8 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1965:75874 CAPLUS
DN 62:75874
OREF 62:13472g-h,13473a
TI Effect of several anabolic steroids on sulfobromophthalein (BSP) retention in rabbits
AU Lennon, Harry D.
SO Steroids (1965), 5(3), 361-73
DT Journal
LA English

L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1962:449501 CAPLUS
DN 57:49501
OREF 57:9913f-i,9914a-h
TI 2 Oxasteroids. New class of biologically active compounds
AU Pappo, Raphael; Jung, Christopher J.
CS G. D. Searle & Co., Skokie, IL
SO Tetrahedron Letters (1962) 365-71
DT Journal
LA Unavailable

=> d l8 2 6-9 all

L8 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1991:254029 CAPLUS
DN 114:254029
TI Compositions useful as contraceptives in males
IN Cohen, Michael
PA Neth.
SO PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K031-56
ICS A61K031-565; A61K031-585; A61K031-57; A61K031-58
ICI A61K031-56, A61K031-40, A61K031-05; A61K031-565, A61K031-40, A61K031-05; A61K031-57, A61K031-40, A61K031-05, A61K031-565; A61K031-585, A61K031-40, A61K031-05, A61K031-565, A61K031-57
CC 63-6 (Pharmaceuticals)

Section cross-reference(s): 2

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9100095	A1	19910110	WO 1990-NL90	19900626
	W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CM, DE, DK, ES, FR, GA, GB, IT, LU, ML, MR, NL, SE, SN, TD, TG				
	IN 171596	A	19921121	IN 1990-MA495	19900620
	CA 2059138	AA	19901228	CA 1990-2059138	19900626
	AU 9059683	A1	19910117	AU 1990-59683	19900626
	AU 639467	B2	19930729		
	DD 297327	A5	19920109	DD 1990-342103	19900626
	EP 479867	A1	19920415	EP 1990-910521	19900626
	EP 479867	B1	19960515		
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
	DD 299619	A5	19920430	DD 1990-344095	19900626
	IL 94869	A1	19941007	IL 1990-94869	19900626
	JP 07507037	T2	19950803	JP 1990-510056	19900626
	AT 137970	E	19960615	AT 1990-910521	19900626
	CN 1048327	A	19910109	CN 1990-103286	19900627
	ZA 9005020	A	19910424	ZA 1990-5020	19900627
PRAI	US 1989-371794		19890627		
	WO 1990-NL90		19900626		

OS MARPAT 114:254029

AB A method of effecting contraception in human males comprises administering a combination of melatonin and an androgenic hormone in a contraceptively effective amt. Optionally, the melatonin and androgenic hormone can be further combined with a progesterone or an estrogen. An administration of melatonin and androgens also provides as method for preventing prostate cancer. Thus, a 23 yr-old male was administered a depot **injection** of melatonin 100 and testosterone enanthate 200 mg on a weekly basis. The patient became azoospermic and contraceptive efficacy was achieved. The injections were continued to maintain azoospermia.

ST contraceptive male melatonin androgen; progesterone melatonin androgen male contraceptive; estrogen melatonin androgen male contraceptive; prostate cancer prevention melatonin androgen

IT Androgens
RL: BIOL (Biological study)
(mixt. with melatonin, for male contraception)

IT Testis, disease or disorder
(azoospermia, induction by melatonin and androgens, for male contraception)

IT Pharmaceutical dosage forms
(implants, s.c., sustained-release, of melatonin and androgen, for male contraception)

IT Pharmaceutical dosage forms
(injections, of melatonin and androgen, for male contraception)

IT Contraceptives
(male, melatonin and androgen combination for)

IT Estrogens
Progestogens
RL: BIOL (Biological study)
(mixts., with androgens and melatonin, for male contraception)

IT Prostate gland
(neoplasm, prevention of, melatonin and androgen combination for)

IT Pharmaceutical dosage forms
(oral, of melatonin and androgen, in individual storage pods, for male contraception)

IT 50-28-2D, Estradiol, mixts. with melatonin and androgen 51-98-9D, Norethindrone acetate, mixts. with melatonin and androgen 52-76-6D,

Lynestrenol, mixts. with melatonin and androgen 53-16-7D, Estrone, mixts. with melatonin and androgen 56-53-1D, Diethylstilbestrol, mixts. with melatonin and androgen 57-63-6D, Ethinyl estradiol, mixts. with melatonin and androgen 67-95-8D, Quingestrone, mixts. with melatonin and androgen 68-22-4D, Norethindrone, mixts. with melatonin and androgen 68-23-5D, Norethynodrel, mixts. with melatonin and androgen 71-58-9D, Medroxyprogesterone acetate, mixts. with melatonin and androgen 72-33-3D, Mestranol, mixts. with melatonin and androgen 73-31-4D, Melatonin, analogs, mixts. with androgens and progestogens 79-64-1D, Dimethisterone, mixts. with melatonin and androgen 297-76-7D, Ethynodiol acetate, mixts. with melatonin and androgen 302-22-7D, Chlormadinone acetate, mixts. with melatonin and androgen 434-22-0D, 19-Nortestosterone, mixts. with melatonin and progestogen 481-97-0D, Estrone sulfate, mixts. with melatonin and androgen 595-33-5D, Megestrol acetate, mixts. with melatonin and androgen 797-63-7D, Levonorgestrel, mixts. with melatonin and androgen 1169-79-5D, Quinestradiol, mixts. with melatonin and androgen 6533-00-2D, Norgestrel, mixts. with melatonin and androgen 134061-43-1, Melatonin-testosterone mixt. 134061-44-2, Melatonin-testosterone propionate mixt. 134061-45-3, Melatonin-testosterone enanthate mixt. 134061-46-4, Melatonin-testosterone cypionate mixt. 134061-47-5, Melatonin-methylestosterone mixt. 134061-48-6, Melatonin-fluoxymesterone mixt. 134061-49-7, Melatonin-danazol mixt. 134061-50-0, Melatonin-methandriol mixt. 134061-51-1, Melatonin-nandrolone decanoate mixt. 134061-52-2, Melatonin-nandrolone phenpropionate mixt. **134061-53-3**, Melatonin-oxandrolone mixt. 134061-54-4, Melatonin-oxymetholone mixt. 134061-55-5, Melatonin-stanozolol mixt. 134095-27-5, Melatonin-testolactone mixt. 134095-28-6 134095-29-7 134095-45-7, Melatonin-dromostanolone propionate mixt. 134117-95-6, Melatonin-ethylestrenol mixt.
RL: BIOL (Biological study)
(male contraceptives contg., for azoospermia induction)

L8 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1970:18865 CAPLUS
DN 72:18865
TI Estrogenic and antiestrogenic activities of a number of steroids in behavioral estrus and vaginal smear assays in the ewe
AU Lindsay, D. R.; Scaramuzzi, R. J.
CS Univ. Sydney, Sydney, Australia
SO Journal of Endocrinology (1969), 45(4), 549-55
CODEN: JOENAK; ISSN: 0022-0795
DT Journal
LA English
CC 4 (Hormones and Related Substances)
AB Fourteen synthetic steroids and androstenedione were examd. in ovariectomized ewes for estrogenic activity when administered alone and with estradiol benzoate by i.m. **injection**. None of the compds. investigated was active when administered alone, as assessed by the vaginal smear assay, and only androstenedione produced a behavioral response. Androstenedione had a min. effective dose of 8.8 mg but was less active when administered i.v. Several steroids acted as antiestrogens when injected with estradiol benzoate. Eight steroids inhibited the behavioral response and 4 the vaginal response. An additive response was found with androstenedione for behavioral response and with 17.beta.-ethyl-17-hydroxy-19-nor-4-androsten-3-one for vaginal response. Vaginal and behavioral responses were not necessarily related, and responses obtained in the ewe to particular steroids were not identical with those obtained in lab. animals by other workers using similar tests.
ST steroids estrogenic; estrogenic steroids; behavior steroids; antiestrogenic steroids
IT Estrogenic hormones

RL: BIOL (Biological study)
(and inhibitors, steroids as, assay techniques in relation to)
IT Estrus
(estrogenic activity of steroids detn. by induction of behavioral, vaginal smear assay in relation to)
IT Vagina
(estrogenic activity of steroids detn. by smear from, behavioral estrus in relation to)
IT Steroids, biological studies
RL: BIOL (Biological study)
(estrogenic and antiestrogenic activities of, in behavioral estrus and vaginal smear assays)
IT 17913-39-2
RL: BIOL (Biological study)
(behavioral estrus and vaginal estrogen response inhibition by)
IT 65-04-3
RL: BIOL (Biological study)
(behavioral estrus and vaginal response inhibition by)
IT 63-05-8
RL: BIOL (Biological study)
(behavioral estrus augmentation and vaginal estrogen response inhibition by)
IT 64-82-4 2061-45-2 2061-46-3 26624-16-8 26624-17-9
RL: BIOL (Biological study)
(behavioral estrus inhibition by)
IT 52-78-8
RL: BIOL (Biological study)
(vaginal estrogen response augmentation by)
IT **26624-15-7**
RL: BIOL (Biological study)
(vaginal estrogen response inhibition by)

L8 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1966:440387 CAPLUS
DN 65:40387
OREF 65:7576b-e
TI Effects of androgens, estrogens, and corticoids on strontium kinetics in man
AU Eisenberg, Eugene
CS Univ. of California, San Francisco
SO J. Clin. Endocrinol. Metab. (1966), 26(5), 566-72
DT Journal
LA English
CC 58 (Hormones)
AB Kinetic studies were made in subjects after intravenous administration of 10 meq. Sr, before and during treatment with steroid hormones, to det. the effects of these agents on the bone deposition rate. Oral administration of fluoxymesterone, oxandrolone, oxymetholone, 7,17-dimethyltestosterone, and norethandrolone (10, 5, 7.5, 1.25, and 20 mg./day) or intravenous **injection** of testosterone enanthate, testosterone caprinoyl ace tate, or nandrolone phenopropionate (200, 200, and 50 mg., resp., every 2 weeks) decreased the urinary excretion rate of Sr, when administered for 6 weeks. Oral administration of conjugated equine estrogen, methallenestrol, ethynylestradiol, or 16.alpha.-methylestriol 16.beta.,17.beta.-3-methyl ether (2.5, 9, 0.1, and 20 mg./day, resp.) similarly decreased the urinary excretion rate and also decreased Sr deposition in bone by .apprx.0.6 l. of miscible pool/24 hrs.; since these were all patients with postmenopausal osteoporosis, this represented .apprx.10% decrease in the bone Sr deposition rate. The androgens and estrogens therefore appear to be anticatabolic for bone, and estrogens may also be antianabolic. Oral administration of cortisol, prednisone, triamcinolone, 6.alpha.fluorotriamcinolone, dexamethasone, or

6.alpha.-fluoroprednisolone (80-120, 20-30, 12-18, 24, 3, or 12 mg./day, resp.) did not decrease the bone deposition rate but did increase the urinary excretion rate of Sr; the corticoids therefore did not appear to be antianabolic for bone. The decrease in bone mass which eventually occurs following corticoid administration is probably the result of accelerated bone resorption. Correction of bone deposition rates of Sr for fecal excretion rates did not affect the results. The results did not show whether the changes in urinary excretion rates induced by both gonadal steroids or glucocorticoids were attributable to effects on the kidney, on bone, or on both. 38 references.

IT Bones
Urine
(strontium in, effect of androgens, corticosteroids and estrogens on)

IT Androgenic hormones or principles
Corticosteroids
Estrogenic hormones or principles
(strontium metabolism response to)

IT Testosterone, heptanoate, mixt. with testosterone propionate
(strontium metabolism response to)

IT 76-43-7, Androst-4-en-3-one, 9-fluoro-11.beta.,17.beta.-dihydroxy-17-methyl- 434-07-1, 5.alpha.-Androstan-3-one, 17.beta.-hydroxy-2-(hydroxymethylene)-17-methyl-
(in strontium metabolism)

IT 7440-24-6, Strontium
(metabolism of, effect of androgens, corticosteroids and estrogens on)

IT 53-34-9, Pregna-1,4-diene-3,20-dione, 6.alpha.-fluoro-11.beta.,17,21-trihydroxy-
(prepn. of)

IT 219-13-6, Cyclopenta[5,6]naphtho[1,2-c]pyran
(steroid derivs., strontium metabolism response to)

IT 50-02-2, Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,17,21-trihydroxy-16.alpha.-methyl- 50-23-7, Cortisol 53-03-2, Pregna-1,4-diene-3,11,20-trione, 17,21-dihydroxy- 124-94-7, Pregna-1,4-diene-3,20-dione, 9-fluoro-11.beta.,16.alpha.,17,21-tetrahydroxy- 807-38-5, Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-
(strontium in urine in response to)

IT 52-78-8, 19-Nor-17.alpha.-pregn-4-en-3-one, 17-hydroxy- **53-39-4**, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-17-methyl- 57-63-6, 19-Nor-17.alpha.-pregna-1,3,5(10)-trien-20-yne-3,17-diol 62-90-8, Estr-4-en-3-one, 17.beta.-hydroxy-, hydrocinnamate 517-18-0, 2-Naphthalenepropionic acid, .beta.-ethyl-6-methoxy-.alpha.,.alpha.-dimethyl- 5108-94-1, Estra-1,3,5(10)-triene-16.beta.,17.beta.-diol, 3-methoxy-16-methyl- 5874-98-6, Testosterone, 3-oxododecanoate 10350-44-4, Androst-4-en-3-one, 17.beta.-hydroxy-7,17-dimethyl-
(strontium metabolism response to)

L8 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1965:75874 CAPLUS
DN 62:75874
OREF 62:13472g-h,13473a
TI Effect of several anabolic steroids on sulfobromophthalein (BSP) retention in rabbits
AU Lennon, Harry D.
SO Steroids (1965), 5(3), 361-73
DT Journal
LA English
CC 58 (Hormones)
AB Routine BSP retention tests were performed on fasted rabbits, blood samples being collected at 5-min. intervals beginning 20 min. after BSP **injection**. Blood samples were clotted and centrifuged at 3000 rpm. for 20 min. and the dye diln. detd. colorimetrically. Bile samples

were obtained by cannulation of the bile duct. The steroids tested were given orally daily for 4 days, except for testosterone propionate (I), which was given intramuscularly. The initial disappearance rate of the dye from blood was 23.9%/min. at 20 mg./kg. The greatest BSP concn. in bile was at 20 min. after **injection** and the av. recovery after 2 hrs. was 82.1%, the major part being excreted during the 1st hr. II, at 10 mg./kg., did not alter, whereas 1 mg. methyltestosterone (III)/kg. slightly increased, 10 mg./kg. caused a 5-fold increase, and 20 mg./kg. further increased BSP-retention in the serum. Norethandrolone (IV) also caused a dose-dependent increase in I-retention, but oxandrolone was much less effective than the III or IV, and failed to demonstrate a clear-cut dose relation.

IT Liver
(-function tests, steroid effect on)

IT Bile
(bromsulfophthalein in, steroid effect on)

IT Androst-4-en-3-one, 17.beta.-hydroxy-17-methyl-(methyltestosterone)
(sulfobromophthalein retention and)

IT **53-39-4**, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-17-methyl-
(effect on sulfobromophthalein retention)

IT 58-22-0, Testosterone
(in sulfobromophthalein retention)

IT 297-83-6, Phenolphthalein, 4,5,6,7-tetrabromo-3',3''-disulfo-
(liver clearance of, anabolic steroid effect on)

IT 316-26-7, Cyclopenta[5,6]naphtho[2,1-c]pyran
(steroid derivs., effect on sulfobromophthalein retention)

IT 52-78-8, 19-Nor-17.alpha.-pregn-4-en-3-one, 17-hydroxy-
(sulfobromophthalein retention response to)

L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2003 ACS
AN 1962:449501 CAPLUS
DN 57:49501
OREF 57:9913f-i,9914a-h
TI 2 Oxasteroids. New class of biologically active compounds
AU Pappo, Raphael; Jung, Christopher J.
CS G. D. Searle & Co., Skokie, IL
SO Tetrahedron Letters (1962) 365-71
DT Journal
LA Unavailable
CC 36 (Steroids)
GI For diagram(s), see printed CA Issue.
AB cf. CA 51, 4330c. Treatment of 1 androstene3,17 dione 16 hrs. at 20.degree. with 4 equivs. Pb(OAc)4 in 905% aq. AcOH and the seco aldehyde reduced with aq. NaBH4 followed by acid treatment yielded 50-60% 17.beta.-hydroxy-2-oxa-3-androstanone (I, R = OH, H) (II), m. 198-203.degree., .lambda. 2.75, 5.78 .mu., [.alpha.]24D 1.0.degree., oxidized with CrO3 to I (R = O), m. 174-5.degree., .lambda. 5.77 .mu.. Similar treatment of 17.beta.-hydroxy-17.alpha.-methyl-1-androsten-3 one (III) led to the corresponding 17.beta.-hydroxy-1-oxo-1,2-seco-A-nor-17.alpha.-methylandrostane-2-carboxylic acid, m. 166-73.degree. (decompn.), 2.77, 2.85, 3.70, 5.80 .mu., [.alpha.]25D -22.5.degree., also obtained by Pb(OAc)4 cleavage of 1.alpha.,2.alpha.,17.beta.-trihydroxy-17.alpha.-methyl-3androstanone, m. 180-8.degree. (decompn.), .lambda. 2.80, 2.89, 5.81 .mu., [.alpha.]26D 15.degree., prepd. by hydroxylation of III with KClO3 in the presence of catalytic amts. of OsO4 in aq. Me3COH. The aldehyde acid reduced with NaBH4 gave 1 (R = OH, Me) (IV), m. 235-8.degree., .lambda. 2.87, 5.79 .mu., [.alpha.]25D -23.degree.. Synthesis of the analogous 4,5-unsatd. compds. proved to be considerably more difficult. Treatment of 1,4-androstadiene-3,17-dione in Me3COH with KClO3 in the presence of OsO4 gave mainly V (R = O), m. 205-9.degree., .lambda. 228 m.mu. (.epsilon. 9500, MeOH), .lambda. 2.80, 2.88, 5.76, 5.93

.mu., [.alpha.]28D 151.degree.. The mother liquors fractionally crystd. yielded 10% 1.alpha.,2.alpha.-dihydroxy-4-androstene-3,17-dione (VI, R = |O), |m. 205-9.degree., .lambda. 238 m.mu. (.epsilon. 13,700), .lambda. 2.80, 2.87, 5.75, 5.95, 6.19 .mu., [.alpha.]27D 168.5.degree.. The ketone cleaved with Pb(OAc)4 in aq. AcOH at about 60.degree. gave VII (R = O) (VIII), m. 250-9.degree., .lambda. 226 m.mu. (.epsilon. 14,000), .lambda. 2.80, 3.00, 5.78, 5.88, 6.12 .mu., [.alpha.]27D 279.5.degree. (existing mainly in the lactol form, 1-hydroxy-2oxa-4-androstene-3,17-dione). VIII in CHCl3 stirred with 1 equiv. NaOH in the presence of excess NaBH4 gave pure 17.beta.-hydroxy-2-oxa-4-androsten-3-one (IX, R = .beta.-OH, H) (X), m. 205-7.degree., .lambda. 223.5 m.mu. (.epsilon. 14,500), .lambda. 2.76, 5.80, 5.88, 6.14 .mu., [.alpha.]28D 173.degree.. Similar treatment of 17.beta.-hydroxy-17.alpha.-methyl-1,4-androstadien-3-one gave predomi-nantly V (R = .beta.-OH, Me) (XI), m. 196-9.degree., .lambda. 229.5 m.mu. (.epsilon. 9350), .lambda. 281, 2.89, 5.93, 6.20 .mu., [.alpha.]26D 57.5.degree.. Fractional crystn. of the mother liquors and removal of residual XI with aq. NaHSO3 in C5H5N gave the required isomeric VI (R = .beta.-OH, Me) (XII), m. 1993.0-5.5.degree., .lambda. 239 m.mu., (.epsilon. 13,300), .lambda. 2.85, 3.00, 5.90, 5.96, 6.1 .mu. (KBr), [.alpha.]27D 63.degree.. XI and XII separately treated with Pb(OAc)4 in AcOH gave 17.beta.hydroxy-3,5-seco-5-oxo-17.alpha.-methyl-A-nor-1-androstene3-carboxylic acid (lactol form, 5,17.beta.-dihydroxy-17.alpha.-methyl-4-oxa-1-androsten-3-one) (XIII), m. 227-30.degree., .lambda. 220 m.mu. (.epsilon. 7500), .lambda. 3.00, 3.15, 5.93, 6.18 .mu., and the lactol VII (R = .beta.-OH, Me) (XIV), m. 250-65.degree., .lambda. 226 m.mu. (.epsilon. 14,200), .lambda. 2.85, 3.05, 5.85, 6.13 .mu. (KBr). Treatment of XIII and XIV in CHCl3 with dil. aq. K2CO3 or Na2CO3 extd. XIII selectively since XIV was only sol. in dil. NaOH. Reduction of XIV in CHCl3 gave 17.beta.-hydroxy-17.alpha.-methyl-2-oxa-4-androsten-3one, (XV), m. 230-40.degree. (decompn.), .lambda. 223.5 m.mu. (.epsilon. 12,500), .lambda. 2.75, 5.78, 5.85, 6.13 .mu., [.alpha.]26D 123.degree.. Application of the same series of reactions to .DELTA.1-progesterone gave a mixt. of 1,2-dihydroxyprogesterone and 4,5-dihydroxy-1-pregnene3,20-dione, converted by treatment with Pb(OAc)4 to a mixt. of VII (R = .beta.-Ac, H) (XVI) and 5-hydroxy-4-oxa-1pregnene-3,20-dione (XVII), sepd. by partition with aq. K2CO3 to give pure XVI, m. 220-3.degree., .lambda. 226.5 m.mu. (.epsilon. 14,300), .lambda. 2.80, 3.00, 5.79, 5.88, 6.12 .mu., [.alpha.]26D 268.degree. (0.5%) and pure XVII, m. 203-6.degree., .lambda. 220 m.mu. (.epsilon. 8300), .lambda. 2.80, 2.97, 5.80, 5.87 .mu., [.alpha.]28D 275.5.degree.. XVI reduced with NaBH4 in a 2 phase system and the epimeric 20-hydroxy compds. oxidized with CrO3 gave IX (R = .beta.-Ac, H) (XVII), m. 168-9.degree., .lambda. 223.9 m.mu. (.epsilon. 14,150), .lambda. 5.80, 5.85, 6.13 .mu., [.alpha.] 26D 237.5.degree.. An analogous series of reactions converted 17.alpha.-acetoxy-.DELTA.1progesterone to 17.alpha.-acetoxy-1-hydroxy-2-oxaprogesterone VII (R = .beta.-Ac, OAc), m. 285.8.degree. (decompn.), .lambda. 226 m.mu. (.epsilon. 14,400), .lambda. 2.75, 2.98, 5.76, 6.10, 7.90 .mu., [.alpha.]24D 137.degree., reduced by NaBH4 in Me2CHOH to give IX (R = .beta.-Ac, OAc) (XVIII), m. 275-9.degree., .lambda. 223.5 m.mu. (.epsilon. 14,900), .lambda. 5.80, 5.83, 6.15, 7.97 .mu., [.alpha.]23D 114.5.degree.. XV is about as anabolic as 17.alpha.-methyltestosterone but only 20% as androgenic by intramuscular **injection** in the levator ani test. IV was more active than 17.beta.-hydroxy-17.alpha.-methyl-3-androstanone as an oral anabolic agent in the N retention test but is essentially devoid by androgenic properties. XVII and XVIII are about as active as progesterone and 17-acetoxy progesterone resp. in rabbits in the Clauberg assay. The biol. equivalence of the 2-oxa corticoids to the corresponding normal steroids is not compatible with the considerable chem. difference between lactones and ketones and it was assumed that the 3-CO group is not involved chemically in the mechanism of biol. action of these hormones.

IT Spectra, infrared
(of 2-oxasteroids and intermediates)

IT Spectra, visible and ultraviolet
(of 4.alpha.,5-dihydroxy-5.alpha.-androst-1-ene-3,17-dione and congeners)
IT 95126-10-6, 2-Oxaandrost-4-ene-3,17-dione, 1-hydroxy-
(equil. with 1,17-dioxo-1,2-seco-A-norandrost-3(5)-en-2-oic acid)
IT 98658-79-8, 7H-Benz[e]indene-.DELTA.7,.alpha.-acetic acid,
6-formyl-1,2,3,3a,4,5,5a,6,8,9,9a,9b-dodecahydro-3a,6-dimethyl-3-oxo-
98843-08-4, 1,2-Seco-A-norandrost-3(5)-en-2-oic acid, 1,17-dioxo-
(in equil. with 1-hydroxy-2-oxaandrost-4-ene-3,17-dione)
IT 104831-96-1, 4-Oxaandrost-1-en-3-one, 5,17.beta.-dihydroxy-17-methyl-
(in equil. with 17.beta.-hydroxy-17-methyl-5-oxo-3,5-seco-A-norandrost-1-en-3-oic acid)
IT 100150-69-4, 1H-Benz[e]indene-6-acrylic acid, 2,3,3a,4,5,5a,6,7,8,9,9a,9b-dodecahydro-3-hydroxy-3,3a,6-trimethyl-7-oxo- 105564-76-9,
3,5-Seco-A-norandrost-1-en-3-oic acid, 17.beta.-hydroxy-17-methyl-5-oxo-
(in equil. with 5,17.beta.-dihydroxy-17-methyl-4-oxaandrost-1-en-3-one)
IT **53-39-4**, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-17-methyl- 794-12-7, 2-Oxa-5.alpha.-androstan-3-one, 17.beta.-hydroxy-
901-87-1, 1,2-Seco-A-nor-5.alpha.-androstan-2-oic acid,
17.beta.-hydroxy-17-methyl-1-oxo- 1805-13-6, 5.alpha.-Androst-1-ene-3,17-dione, 4.alpha.,5-dihydroxy- 26609-24-5, 2-Oxapregn-4-ene-3,20-dione
38851-97-7, 2-Oxaandrost-4-en-3-one, 1,17.beta.-dihydroxy-17-methyl-
63973-71-7, 2-Oxaandrost-4-en-3-one, 17.beta.-hydroxy- 92473-02-4,
2-Oxaandrost-4-en-3-one, 17.beta.-hydroxy-17-methyl- 94003-59-5,
2-Oxa-5.alpha.-androstane-3,17-dione 94761-20-3, 5.alpha.-Androstan-3-one, 1.alpha.,2.alpha.,17.beta.-trihydroxy-17-methyl- 95172-05-7,
2-Oxapregn-4-ene-3,20-dione, 17-hydroxy-, acetate 95585-10-7,
5.alpha.-Androst-1-en-3-one, 4.alpha.,5,17.beta.-trihydroxy-17-methyl-
95720-13-1, Androst-4-ene-3,17-dione, 1.alpha.,2.alpha.-dihydroxy-
95946-65-9, 2-Oxapregn-4-ene-3,20-dione, 1-hydroxy- 96002-84-5,
2-Oxapregn-4-ene-3,20-dione, 1,17-dihydroxy-, 17-acetate 96478-50-1,
Androst-4-en-3-one, 1.alpha.,2.alpha.,17.beta.-trihydroxy-17-methyl-
99729-06-3, 1H-Benz[e]indene-7-acetic acid, 6-formyldodecahydro-3-hydroxy-3,3a,6-trimethyl- 100194-71-6, 4-Oxapregn-1-ene-3,20-dione, 5-hydroxy-
(prepn. of)
IT 219-13-6, Cyclopenta[5,6]naphtho[1,2-c]pyran 219-18-1,
Cyclopenta[5,6]naphtho[2,1-b]pyran
(steroid derivs.)

=> d his

(FILE 'HOME' ENTERED AT 13:01:20 ON 03 APR 2003)

FILE 'REGISTRY' ENTERED AT 13:01:28 ON 03 APR 2003
L1 8 S OXANDROLONE

FILE 'CAPLUS' ENTERED AT 13:02:16 ON 03 APR 2003
L2 239 S L1
E DERMAL
L3 11724 S E3
L4 0 S L3 AND L2
E THERAPUTIC
L5 190608 S E3-E8
L6 41 S L2 AND L5
E INJECTION
L7 410596 S E3
L8 9 S L7 AND L2

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	141.55	148.06

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.46	-8.46

STN INTERNATIONAL LOGOFF AT 13:32:21 ON 03 APR 2003